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ABSTRACT 
Vitamin D deficiency and/or insufficiency is common in US adults and is linked 
to increased chronic disease risk.  With the identification of vitamin D metabolizing 
enzymes and the vitamin D receptor in many tissues throughout the body, vitamin D 
may play a critical role in many bodily processes that effect numerous disease states 
affecting millions of Americans.  Older adults are at increased risk of vitamin D 
deficiency and/or insufficiency due to decreased cutaneous vitamin D synthesis, low 
sun exposure, high sunscreen use, and low vitamin D content in the food supply.  
Identifying a low vitamin D status and correcting it could be an easy initial step for 
many individuals to improve their overall health and reduce their chronic disease risk.  
PURPOSE:  The purpose of the present study was to investigate the relationship 
between current vitamin D status and risk factors (components of metabolic syndrome 
and cognitive function) for numerous chronic diseases (cardiovascular disease, diabetes, 
dementia) in men and women aged 50-70 years.  METHODS:  Seventy-two (72) 
Caucasian recreationally active older individuals (54 females, 18 males) aged 50-70 
years old completed this cross-sectional study.  Subjects completed a medical history, 
food frequency, sun exposure, and international physical activity questionnaire.  
Subjects had a fasting blood draw taken and lipid panel, glucose, and vitamin D values 
were measured.  The testing visit (~1 hour) included measuring height, weight, waist 
circumference, peripheral blood pressure, central blood pressure and arterial stiffness 
(via Pulse Wave Analysis), % body fat (DXA scan), and cognitive function (a specific 
battery of computerized tests utilizing the Automated Neuropsychological Assessment 
Metrics (ANAM) test system).  Two-way ANOVA (Physical Activity, Gender) was 
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used to determine group differences for all outcome measures based on physical activity 
and gender.  Pearson correlation coefficients were used to explore potential 
relationships between serum 25(OH)D levels and disease risk factors.  A one-way 
ANOVA was used to evaluate potential differences across the three levels of vitamin D 
status (Deficient, Insufficient, Sufficient) for each risk factor for chronic disease.  
Vitamin D status was also utilized in multiple Chi-Square analyses (gender, physical 
activity, ANAM scores, vitamin D synthesis (time of year –ability to synthesize vitamin 
D from the sun or not)).  Statistical significance was set at α=0.05.  RESULTS:  
Exactly 50% (36 out of 72) of the study population were vitamin D deficient (9) or 
insufficient (27).  Deficient and/or insufficient vitamin D status was associated with 
GLU, TGs, % BF, and A/G Ratio.  When evaluating the correlation between circulating 
vitamin D levels (25(OH)D) and risk factors, males had a stronger correlation vs. 
females.  For males the correlations were moderate as vitamin D levels were negatively 
correlated with P_SP (r = -0.557; p=0.016), P_MEANP (r = -0.496; p=0.036); C_SP (r 
= -0.534; p=0.022).   For females, the correlations were significant but weak as vitamin 
D levels were negatively correlated with GLU (r = -0.386; p=0.004), TG (r = -0.296; 
p=0.030), A/G Ratio (r = -0.425; p=0.001).   No significant main effect for gender for 
dietary vitamin D (p=0.171) or for physical activity for dietary vitamin D (p=0.105) was 
detected.  No significant main effect for gender for supplemental vitamin D (p=0.254) 
or for physical activity for supplemental vitamin D (p=0.695) was detected.  The 
correlation between dietary vitamin D and circulating levels of vitamin D was low and 
not significant (r = 0.171; p=0.152) and gender and physical activity had minimal effect 
on these relationships.  All the correlations between circulating levels of vitamin D and 
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cognitive test scores were low and not significant.  70% (7 out of 10) of the subjects in 
the low physical activity group were vitamin D deficient and/or insufficient vs. 51.5% 
(17 out of 33) and 41.4% (12 out of 29) for the moderate and high physical activity 
groups respectively.  There is a strong association between vitamin D status and the 
time of year you get your vitamin D levels measured (p=0.036).  The inability to 
synthesize vitamin D during the winter months significantly affects vitamin D status, as 
62.5% of subjects tested from November to February did not have sufficient vitamin D 
status.  CONCLUSION:  A high percentage (50%) of this study population was 
vitamin D deficient and/or insufficient, and it went up to 70% if you were in the low 
physical activity group.  Deficient and/or insufficient vitamin D status is associated with 
risk factors for chronic disease, as levels for GLU, TGs, % BF, and A/G Ratio all 
decreased with improved vitamin D status.  It is more difficult to maintain a sufficient 
vitamin D status (> 30ng/ml) during the winter months when most people in the US 
cannot synthesize vitamin D from the sun.  Individuals need to pay attention and be 
more diligent with their dietary and possibly supplemental vitamin D intake, especially 
during the winter months, in order to maintain a sufficient vitamin D status and take 
advantage of all the potential benefits vitamin D has to offer for overall health and 
reduced chronic disease risk. 
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CHAPTER I 
INTRODUCTION 
 There is a renewed interest in vitamin D research, as vitamin D publications 
have notably increased over the last decade.  A new Institute of Medicine (IOM) report 
on vitamin D (and calcium) changed the vitamin D recommendations, which vitamin D 
researchers largely disagreed with and as a result have published over 12,000 vitamin D 
articles since the IOM report in 2011 (46, 102, 110).  There is good reason for this 
renewed interest, as vitamin D deficiency is common in US adults, especially among 
minority groups (36, 44, 53, 54, 65, 117), and with recent discoveries of critical roles 
played by vitamin D in many other bodily processes besides calcium and bone 
metabolism (58, 59, 61), correcting deficiencies/insufficiencies could have many 
beneficial effects for numerous disease states affecting millions of Americans.  Recent 
discoveries of a vitamin D receptor (VDR) in multiple cell types as well as the presence 
of the activating vitamin D enzyme (1α-hydroxylase) in many tissues (3, 28, 29, 72) has 
led to an appreciable spike in the research of possible non-skeletal benefits of vitamin 
D, although some controversy exists over which tissues actually express the VDR due 
to the amount of the receptor present and the quality of the antibodies utilized (124, 
126). 
 Recent Institute of Medicine (IOM) recommendations (102) for vitamin D (600 
IU/day for 1-70 yrs. old, 800 IU/day for >70 yrs. old), according to prominent expert 
vitamin D researchers, seem to have been created with only skeletal health benefits in 
mind, and even skeletal needs require higher recommendations according to these 
experts.  Interestingly, due to perceived skin cancer risk and variability in cutaneous 
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vitamin D synthesis via ultraviolet (UV) light, these new Recommended Dietary 
Allowances (RDAs) for vitamin D were created for an individual receiving minimal sun 
exposure.  Non-skeletal benefits of vitamin D were deemed inconclusive in the IOM 
report due to insufficient evidence in their opinion, yet their new recommendations 
appear insufficient and inconsistent with results seen by leading vitamin D 
researchers(57).  Complicating this issue even further is the fact that overweight or 
obese individuals (~2/3 of the population) have a more difficult time raising their 
vitamin D status with intake at the new Dietary Reference Intake (DRI) levels(41, 57, 
77, 132).  This inconsistency with modern research results and seemingly blatant 
disregard for the status and size of the US population seems to undermine the credibility 
of the IOM report for these new vitamin D recommendations.   
 Vitamin D’s history is linked with the childhood bone disease rickets, with 
vitamin D deficiency being a by-product of the Industrial Revolution.  This 
industrialization of cities led to many new tall buildings, increased pollution, and 
increased indoor activity, all of which decreased exposure to sunshine and the optimal 
endogenous production of vitamin D.  It was suspected by numerous doctors that 
exposure to sunlight had something to do with bone development, but this theory was 
panned by the scientific community, as they could not accept that simply exposure to 
sunlight could cure this bone-deforming disease.  Decades passed with minimal 
progress in curing rickets for the rest of the 19
th
 century, and by the dawn of the 20
th
 
century, rickets was rampant in industrialized cities across Europe and the US.  Early in 
the 20
th
 century, the link between sunlight and skeletal health was more widely 
accepted, with vitamin D being discovered in the 1920’s by scientists such as Mellanby, 
3 
 
 
McCollum, Huldshinsky, and Steenbock and the structure of vitamin D uncovered soon 
after in the early 1930’s(29, 55).  Unfortunately, rickets is not a disease that disappeared 
with the discovery of vitamin D, as lately cases are on the rise again.  This is due to a 
number of reasons, including low vitamin D content in human breast milk, children 
spending too much time indoors, increased sunscreen use, and increased use of 
protective clothing when outdoors(29, 65). 
 The major source of vitamin D in humans is exposure of the skin to sunlight, 
specifically ultraviolet B (UVB) radiation that is between 290-315 nm.  These UVB 
photons are absorbed by 7-dehydrocholesterol (7-DHC) in the skin and quickly form 
previtamin D3.  This unstable previtamin D3 thermally isomerizes to vitamin D3 which 
can then bind to the vitamin D binding protein (DBP) in the circulation as it travels to 
the liver.  In the liver it is converted to 25-hydroxyvitamin D (25(OH)D), which is the 
major circulating form of vitamin D and is also what is measured to determine an 
individuals’ vitamin D status.  Vitamin D is unique in that the major circulating form 
(25(OH)D) that is measured to determine vitamin D status is not actually the active 
form.  25(OH)D has to travel to the kidneys where it is converted to 1,25-
dihydroxyvitamin D (1,25(OH)2D).  This active form (1,25(OH)2D) then enters the 
circulation to travel to target tissues that regulate calcium metabolism, such as the 
intestine (66).  1,25(OH)2D interacts with a vitamin D receptor (VDR) in the intestine to 
increase epithelial calcium channels to enhance calcium transport into the absorptive 
cell.  1,25(OH)2D also helps calcium transport across the absorptive cell into the 
circulation via increased expression of a calcium binding protein (calbindin9k) (26, 27).  
Since vitamin D is necessary for proper absorption of calcium in the small intestine, it 
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helps ensure adequate calcium deposition to the bones to give them their strength.  In 
addition to the importance of maximizing your peak bone density in your adolescence 
and early twenties, vitamin D continues to play a crucial role in bone health throughout 
later life.  Bone is very metabolically active, continually being broken down and rebuilt 
(bone remodeling) throughout your life.  Unfortunately, starting in your late 30’s you 
begin to break down more bone than is rebuilt, thus throwing off this remodeling 
process slightly in favor of a gradual loss of bone density and increased fragility as you 
age.  Adequate vitamin D intake and status will help maximize calcium absorption, 
leading to normal bone mineralization, and will help minimize and slow this improper 
remodeling as you age. 
 So why is our vitamin D status poor and getting worse?  People get a very high 
percentage (90-95%) of their vitamin D requirement from exposure to sunlight, 
specifically exposure to ultraviolet B (UVB) radiation.  Unfortunately, most adults in 
the US do not go outside in the sun enough to meet their vitamin D needs year round.  
Also, during the winter months, it is not possible in much of the US (above 33° north 
latitude (Atlanta, GA)) (67, 127, 129) for cutaneous vitamin D production.   Combine 
this with the added obstacles for individuals with darker skin (due to increased melanin 
content, which decreases vitamin D synthesis) and older individuals (less 7-DHC 
content in skin with aging) and you start to understand why many adults, especially 
older adults are vitamin D insufficient and deficient (47, 51).  UVB is the only form of 
UV radiation that is absorbed by the vitamin D precursor in the skin to make vitamin D.  
The mass media has increased the coverage of the potential benefits of vitamin D, 
leading to more patients asking their doctors about their vitamin D status, and the 
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25(OH)D assay is now one of the most ordered assays in the US (65).  But with the 
previously mentioned increase in sunscreen use and less time spent outdoors, combined 
with the fact that vitamin D is not widely available in the food supply, many individuals 
are at risk for vitamin D deficiency.   
It is noteworthy to highlight the challenges that go into accurately assessing 
vitamin D status.  It is important to use a combination of a blood 25(OH)D 
measurement along with questions regarding one’s dietary (food and supplemental) 
vitamin D intake and sunlight exposure (87).  Sunlight questionnaires need to be 
comprehensive enough so that they take into account all the factors that affect one’s 
personal UVB exposure and vitamin D synthesis via skin.  These factors include 
latitude, season, time of day, sunscreen use, age, clothing, and skin type (30, 35, 85, 
127, 128).  Vitamin D status is determined by measuring 25(OH)D levels in the blood, 
which is the major circulating form of vitamin D.  25(OH)D includes vitamin D intake 
from food and vitamin D from UVB exposure, and has a half-life of ~2-3 weeks (64).  
While 25(OH)D is not the biologically active form (1,25(OH)2D), its circulating levels 
are 1000 times more than 1,25(OH)2D.  Combine that with the fact that 1,25(OH)2D has 
a half-life of only 4-6 hours, and it is clear that measuring 25(OH)D is the best option 
(59, 62, 64). 
 Most experts agree that vitamin D deficiency be defined as having a 25(OH)D 
level of <20 ng/ml, and vitamin D insufficiency is between 21-29 ng/ml.  Ideally, a 
level of >30 ng/ml is preferred by most experts (64, 65).  This level of >30 ng/ml is very 
difficult to reach if you don’t have consistent sensible sun exposure, but the public is 
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being frightened over the past few decades by the pharmaceutical industry and 
dermatologists to avoid the sun at all times.  These industries have deep pockets to get 
their message out to the public that ―no amount of unprotected sun exposure is sensible 
or important for health‖ (65), and to use their sunscreen products constantly in this 
youth obsessed society.  A balance needs to be struck though, as it is important to point 
out that you can take advantage of all the benefits of sensible sun exposure while 
minimizing its aging effects or skin cancer risk(88).  The research to be covered in the 
next chapter will illustrate that sensible sun exposure and adequate vitamin D status 
appear to reduce many chronic disease risk factors and risk for cognitive dysfunction 
(memory, attention, processing speed), and this benefit far outweighs any skin cancer 
risk or premature aging from exposure to UVB radiation. 
Purpose 
 The purpose of the present study was to investigate the relationship between 
current vitamin D status and risk factors (components of metabolic syndrome and 
cognitive dysfunction) for numerous chronic diseases (cardiovascular disease, diabetes, 
dementia) in men and women aged 50-70 years.  This study aimed to determine if 
deficient and/or insufficient vitamin D status is associated with risk factors (components 
of metabolic syndrome and cognitive dysfunction) for chronic disease (cardiovascular 
disease, diabetes, dementia). 
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Research Questions 
1. What is the prevalence of deficient and/or insufficient vitamin D status in a 
sample of older subjects? 
2. Is a deficient and/or insufficient vitamin D status associated with risk factors 
(components of metabolic syndrome and cognitive dysfunction) for chronic 
disease (cardiovascular disease, diabetes, dementia)? 
3. Does circulating vitamin D levels (25(OH)D) affect risk for chronic disease and 
are these relationships different for males and females? 
4. Does dietary intake of vitamin D differ based on gender or physical activity? 
5. Does supplemental intake of vitamin D differ based on gender or physical 
activity? 
6. Is the relationship between dietary intake of vitamin D and circulating levels of 
vitamin D (25(OH)D) different based on gender or physical activity? 
7. Does circulating vitamin D levels (25(OH)D) correlate with Throughput scores 
on cognitive tests? 
Research Subquestions 
1. A) What is the prevalence of deficient and/or insufficient vitamin D status based 
on gender? 
B) What is the prevalence of deficient and/or insufficient vitamin D status based 
on physical activity level? 
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2. A) Is a deficient and/or insufficient vitamin D status associated with risk factors 
(components of metabolic syndrome and cognitive dysfunction) for chronic 
disease (cardiovascular disease, diabetes, dementia) differently based on gender?  
B) Is a deficient and/or insufficient vitamin D status associated with risk factors 
(components of metabolic syndrome and cognitive dysfunction) for chronic 
disease (cardiovascular disease, diabetes, dementia) differently based on 
physical activity levels? 
Research Hypotheses 
1. The vitamin D status of at least 50% of these older individuals will be deficient 
and/or insufficient. 
2. Deficient and/or insufficient vitamin D status will be associated with chronic 
disease risk factors. 
3. Circulating vitamin D levels (25(OH)D) will correlate with risk factors for 
chronic disease and males will have stronger correlations with risk factors for 
chronic disease vs. females. 
4. Dietary intake of vitamin D will not differ based on gender or physical activity 
level. 
5. Supplemental intake of vitamin D will not differ based on gender or physical 
activity level. 
6. Correlations between dietary intake of vitamin D and circulating levels of 
vitamin D (25(OH)D) will not differ based on gender or physical activity level. 
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7. Circulating vitamin D levels (25(OH)D) will not correlate with Throughput 
scores on cognitive tests. 
Research Subquestion Hypotheses 
1. A) The prevalence of deficient and/or insufficient vitamin D status will be 
greater in males vs. females. 
B) The prevalence of deficient and/or insufficient vitamin D status will be 
greater in the low physical activity group vs moderate or high physical activity 
group. 
2. A) Males with a deficient and/or insufficient vitamin D status will be associated 
with more risk factors for chronic disease vs. females with a deficient and/or 
insufficient vitamin D status. 
B) Subjects in the low physical activity group with a deficient and/or insufficient 
vitamin D status will not see a significant difference in risk factors for chronic 
disease (across levels of vitamin D status) vs subjects in the moderate or high 
physical activity groups with a deficient and/or insufficient vitamin D status. 
Significance of the Study 
 There appears to be a renewed interest in researching vitamin D, as annual 
citations in the PubMed database on vitamin D have doubled in the past decade (2).   
Also in the first decade of the 21
st
 century the amount of money spent on vitamin D 
supplements has increased tenfold from ~$40 million/yr. to over $400 million/yr. (84).  
The reason for this is that vitamin D deficiency is common in the US adult population, 
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and with its deficiency linked to increased chronic disease risk and all-cause mortality 
(36, 76), testing for vitamin D deficiency may need to be part of future chronic disease 
risk screening procedures.  Vitamin D deficiency is common due to the fact that it is not 
widely available in the food supply and thus very difficult to meet needs through diet 
alone.  Combine this with the fact that the public has been bombarded by the antisun 
campaigns (pharmaceutical companies and dermatology profession) that any sun 
exposure should be avoided or only done with their sunscreen products used, it becomes 
very difficult to maintain adequate vitamin D status.  Even the government backed 
Healthy People 2010 stated an objective that included protective measures to avoid sun 
exposure during peak hours (10am-4pm) and utilize sunscreen and protective clothing 
when exposed to sun (85).  In fact, a SPF 15 decreases your ability to make vitamin D 
by about 95%, and an SPF 30 reduces your ability by 99% (65).  With everybody 
constantly using SPF products and with US society experiencing a worsening obesity 
epidemic, which is linked to vitamin D deficiency/insufficiency (2), now is the time to 
look at vitamin D’s link to chronic disease risk and hopefully checking vitamin D status 
will become commonplace in attempting to halt chronic disease progression. 
Assumptions 
1. Subjects answered the questionnaire addressing their nutrition history, sunlight 
exposure and their medications use honestly and accurately. 
2. DXA was a valid and reliable method for measuring % body fat and A/G Ratio.  
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Delimitations 
1. Men and women aged 50-70 years old. 
2. Participants were recruited from Norman, OK (USA) and surrounding 
communities. 
3. DXA (Lunar Prodigy, Madison) was used for measuring % body fat and 
android/gynoid (A/G) ratio. 
Limitations  
1. Since data was collected in Norman, OK, the results may not be applicable for 
older individuals with different ethnicities/composition compared to the 
population of Norman, OK. 
2. All subjects participating in the study were volunteers and therefore may not 
accurately represent the population of older individuals. 
3. This study is a cross-sectional design, thus no cause and effect relationship can 
be implied. 
Inclusion Criteria 
1. Men and women aged 50-70 years old. 
2. Subjects weighing no more than 300 lbs. which is the weight limit of the DXA 
machine. 
3. Subjects should have no cognitive problems that can interfere with their 
participation.  Subjects must score greater than or equal to 27 points (out of 30) 
on the Mini Mental State Examination (MMSE) to indicate a normal cognition. 
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4. Subjects should be able to speak and understand English. 
Exclusion Criteria 
1. Individuals <50 years old or > 70 years old. 
2.  Subjects weighing more than 300 lbs. 
3. Subjects with cognitive impairment that does not allow them to complete the 
current process or testing.  Subjects scoring less than 27 points (out of 30) on the 
MMSE. 
Operational Definitions 
1. Vitamin D status – Refers to levels of 25-hydroxyvitamin D, the major 
circulating form of vitamin D in the blood.  The unit of measurement used for 
vitamin D is nanograms per milliliter (ng/ml).  2.5 nmol/L = 1 ng/ml  
2. Rickets – A vitamin D deficiency disease seen in children, which leads to a 
softening and weakening of the bones. 
3.  Osteoporosis - A disease of the skeleton characterized by low bone mineral 
density and micro-architectural deterioration, leading to bone fragility and 
increased risk of fracture. 
4. Ultraviolet B Radiation (UVB) – invisible radiation that comes from the sun 
with wavelengths of 290-315 nm. 
5. Metabolic Syndrome – A name for a group of risk factors that occur together 
and increase the risk for cardiovascular disease, stroke, and type II diabetes.  
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According to the American Heart Association, metabolic syndrome is present if 
someone has any 3 of the following symptoms: 
 Blood pressure equal to or higher than 130/85 mmHg 
 Fasting blood sugar (glucose) equal to or higher than 100 mg/dL 
 Large waist circumference (length around the waist): 
- Men – 40 inches or more 
- Women – 35 inches or more 
 Low HDL cholesterol: 
- Men – under 40 mg/dL 
- Women – under 50 mg/dL 
 Triglycerides equal to or higher than 150 mg/dL 
6. Alzheimer’s Disease (AD) – The most common form of dementia, AD is a 
progressive disorder that affects memory, thinking, and behavior. 
7. Dementia – A more general term that refers to a loss of brain function that 
occurs with certain diseases.  It affects memory, thinking, language, judgment, 
and behavior. 
8. Vascular Dementia – The 2nd most common form of dementia.  High blood 
pressure, high cholesterol, atherosclerosis, and diabetes are all risk factors for 
vascular dementia. 
9. Hypovitaminosis D – A 25(OH)D level of less than 30 ng/ml. 
10. Dual Energy X-Ray absorptiometry (DXA): Body composition modality that 
uses two contrasting x-ray beams to yield total and regional lean body mass. 
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DXA calculates the attenuation values of photons that pass from the x-ray tube 
through the measurement site of interest.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
15 
 
 
CHAPTER II 
REVIEW OF LITERATURE 
Introduction 
 The role of vitamin D in calcium metabolism and bone health is well 
documented, and while this remains front and center in its function, new biological 
processes have recently been identified for vitamin D that expands its impact and calls 
for a reevaluation of the current intake recommendations.  With the discovery of 
vitamin D receptors and 1α-hydroxylase enzyme in multiple tissues throughout the 
body, these tissues can convert 25(OH)D to 1,25(OH)2D locally, exerting an autocrine 
effect that can influence the expression of hundreds of genes in these tissues (97, 115).  
Holick (60, 61) suggests that these tissues and cells will be able to produce enough 
1,25(OH)2D for local biological functions only if circulating levels of 25(OH)D are 
above 30 ng/ml.  This is very difficult to attain through dietary means, as there are few 
foods that naturally contain vitamin D.  Fatty fish (salmon, mackerel), egg yolks, and 
cod liver oil are a few examples, and fortified foods (milk, yogurt, orange juice, grains) 
offer 100 IU per serving.  Thus, if you are someone that does not eat fish regularly or 
skips breakfast, which millions of Americans do, then your dietary vitamin D intake 
will be very low.  For every 100 IU of vitamin D ingested daily, the blood level of 
25(OH)D increases by 1 ng/ml (56).  Thus, many experts recommend 1000-2000 IU of 
vitamin D/day to maintain vitamin D sufficiency and maximize the potential benefits 
through local production and autocrine action (62).  This local production of 
1,25(OH)2D never enters the circulation to effect calcium metabolism, as this could be 
dangerous.  Instead it is self-regulated through the activity of 24-hydroxylase to create 
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24,25(OH)2D, which was discovered shortly after the discovery of vitamin D.  This 24-
hydroxylation breaks down 1,25(OH)2D to calcitroic acid, which is biologically inactive 
and is excreted in the bile (13, 63, 68, 92).  Thus after performing its local duties, 
1,25(OH)2D self-destructs and the process repeats itself as needed as long as substrate 
supplies (25(OH)D) are sufficient.   
 With these recent discoveries of 1,25(OH)2D production in many tissues 
throughout the body, it then becomes paramount to optimize your substrate (25(OH)2D) 
levels to reap the potential benefits.  Unfortunately, overweight and obesity have an 
inverse relationship with 25 (OH)D levels (19, 70, 74, 90, 100, 132), and with ~2/3 of 
the population either overweight or obese, this appears to be one more hurdle for the 
population to attain sufficient vitamin D status.  Combine this with the low sun 
exposure, high sunscreen use, and low vitamin D content in the food supply, and it 
becomes clear why no one is immune to vitamin D deficiency and why high rates of 
vitamin D deficiency have been seen in the US and throughout the world (36, 44, 59, 
60, 62). 
 The purpose of the present study was to investigate the relationship between 
current vitamin D status and risk factors (components of metabolic syndrome and 
cognitive dysfunction) for numerous chronic diseases (cardiovascular disease, diabetes, 
dementia) in men and women aged 50-70 years.  This study aimed to determine if 
deficient and/or insufficient vitamin D status is associated with an increased number of 
risk factors (components of metabolic syndrome and cognitive dysfunction) for chronic 
disease (cardiovascular disease, diabetes, dementia).  The sections of this chapter are 
17 
 
 
presented in the following order: 1) Vitamin D activation and metabolism, 2) Vitamin D 
and overweight/obesity, 3) Vitamin D and type 2 diabetes, 4) Vitamin D and 
cardiovascular disease, 5) Vitamin D and cognitive function, and 6) Summary. 
Vitamin D Activation and Metabolism 
 With vitamin D available from a scarce number of natural food sources, 
production of vitamin D via the skin has been the most important source of vitamin D 
for the vast majority of individuals.  UVB radiation is absorbed by 7-dehydrocholesterol 
(7-DHC; provitamin D3), a cholesterol precursor located within the triglycerides in the 
plasma membranes of skin cells in the epidermis.  This causes the photolysis of 7-DHC, 
which causes a conformational change and previtamin D3 is formed in the keratinocytes 
of the epidermis.  This is a tightly regulated process so that humans cannot experience 
vitamin D intoxication due to excess sun exposure.  With continued sun exposure, only 
~15% of 7-DHC is converted to and remains previtamin D3, and the rest is converted 
into biologically inactive metabolites (lumisterol, tachysterol).  A similar situation 
occurs at the next step with the cutaneously synthesized vitamin D3, as continued excess 
sun exposure will induce the vitamin D3 to absorb the UVB radiation and be converted 
and photodegraded to suprasterols and metabolites with no calcemic activity.  These 
photoproducts do have potential positive biologic effects and are being investigated for 
possible anti-tumor and antiproliferative activity in skin cells, thus sensible sun 
exposure results in cutaneously produced vitamin D3 and photoproducts that may offer 
additional benefits over simple dietary and/or supplemental vitamin D3.  Under a more 
sensible, non-excessive sun exposure scenario, the formed previtamin D3 is unstable 
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and is fairly rapidly (~50% within 2 hours) converted to vitamin D3, leaves the plasma 
membrane, and diffuses into the dermal capillary network where it binds to vitamin D 
binding protein (DBP) and is transported to the liver (116, 120).  Vitamin D binding 
protein (Gc-globulin) is a multifunctional plasma protein that is synthesized and 
secreted by hepatocytes, and is the major transporter of vitamin D and its metabolites in 
the circulation.  Vitamin D binding protein is a highly polymorphic protein, and the 
effect of DBP polymorphism on circulating 25(OH)D levels has been studied, as well as 
the response to oral vitamin D supplementation (17, 24, 38, 123).  When vitamin D 
deficiency is present, it is currently not known the exact role the DBP polymorphism 
plays.  Does it simply involve a difference in binding capacity or are there problems 
during multiple points along the vitamin D endocrine system.  The precise role of DBP 
when 25(OH)D is delivered to extra renal tissues is still unclear, as there is a ―free 
hormone‖ hypothesis that states that 25(OH)D not bound to DBP (~1%) is more 
bioavailable and free to cross the cell membrane.  If a person or ethnic group has a DBP 
genotype that exhibits a lower binding capacity, how does this affect the amount of 
1,25(OH)2D created and the influence it eventually could have on a large number of 
biologic pathways that affect chronic disease risk (130).  Vitamin D3 created in the skin 
is metabolically inactive and must still be converted to its final active hormone form via 
a two-step hydroxylation.  The first hydroxylation step occurs in the liver and involves a 
25-hydroxylation (via 25-hydroxylase) to produce 25(OH)D, the major circulating form 
found in the blood and the form used to determine vitamin D status.  The second 
hydroxylation step is catalyzed by 1α-hydroxylase to create the active form, 
1,25(OH)2D.  With 25(OH)D and 1,25(OH)2D being discovered over 40 years ago, the 
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search for the enzymes responsible for vitamin D activation was the next challenge.  
The enzyme CYP27B1 was confirmed in 1997 as the sole 1α-hydroxylase in all tissues 
for the creation of the active form (37, 89, 107, 111, 113).  On the other hand, the search 
for the specific enzyme catalyzing the 25-hydroxylation step has proven much more 
difficult.  Recent evidence points to the enzyme CYP2R1 as being of major importance 
in the bioactivation of vitamin D3 in humans, but it is too early to completely discount 
other 25-hydroxylases, including any that may still be discovered (135).   
 The end result is the active form of vitamin D, 1,25(OH)2D, which binds to the 
vitamin D receptor (VDR), a transcriptional factor, to regulate gene expression.  The 
VDR is a member of the nuclear receptor superfamily acting as a ligand-induced (via 
1,25(OH)2D) transcription factor.  This complex combines with the retinoid X receptor 
(RXR) to form a heterodimer, which then binds to specific vitamin D response elements 
(VDREs) to initiate transcription in the regulatory region of vitamin D target genes.  
Until recently it was thought that the VDR is expressed in most cells of the body, but 
with advancing scientific techniques, the identification of a highly specific VDR 
antibody puts this train of thought in serious doubt.  With the majority, if not all vitamin 
D functions being mediated by the VDR, accurately identifying VDRs in tissues 
throughout the body is critical to understanding the biological significance of vitamin D 
and uncovering potential novel therapies involving the VDR (124, 126). 
 The VDR is found in a number of tissues besides those associated with classic 
vitamin D functions (kidney, bone, intestine, parathyroid gland).  These numerous non-
classic potential targets for 1,25(OH)2D are currently evolving and under investigation, 
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but evidence seems to indicate a role for vitamin D beyond its role in regulating calcium 
homeostasis and bone formation.  Caution should be taken though as clarification of 
VDR expression in tissues such as brain, heart, muscle, and liver needs to occur with 
specific and sensitive VDR antibody along with a proper negative control.  Many 
previous antibodies used to identify VDR in various target tissues have been found to 
interact nonspecifically with unknown proteins which could explain a potential false 
positive for VDR expression.  Thus Wang et al recently identified an antibody (D-6) 
that is highly specific, sensitive, and versatile for identifying VDR in target tissues 
utilizing numerous immunological methods (124).  There are still a number of questions 
that need to be answered regarding VDR expression.  How much VDR expression in a 
tissue is needed or is optimal for function?  What is the function of VDR in certain 
tissues?  (There are high levels of VDR expression in tissues where the function has yet 
to be definitively determined (pancreas, keratinocytes))  What role do factors such as 
vitamin D status, age, and health have on VDR expression in tissues?  Does isolating 
cells from tissues or using cultured cells affect VDR expression and thus gene 
transcription?  Answering these questions will go a long way to better understanding the 
function of vitamin D in the cells and tissues where VDR expression is definitely found.  
As we progress through the following sections, VDR expression in the cells/tissues 
involved with the chronic disease risk factors will be discussed.  When we are 
discussing VDR expression in relation to chronic disease risk factors, researchers are 
essentially investigating VDR playing a protective role against these conditions.  With 
research ongoing at all these possible sites of VDR expression, there is also evidence of 
extra renal expression of CYP27B1 so that numerous tissues can synthesize 
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1,25(OH)2D and are capable of autocrine/paracrine functions.  With this capability, it is 
also important that these tissues have the ability to degrade 25(OH)D and 1,25(OH)2D 
so that excess amounts do not get into the bloodstream, influence calcium metabolism 
and lead to hypercalcemia.  This inactivation of active vitamin D is accomplished by the 
catabolic mitochondrial 24-hydroxylase enzyme CYP24A1, which is transcriptionally 
induced by 1,25(OH)2D in these extrarenal tissues.  With CYP27B1 enabling cellular 
concentrations of 1,25(OH)2D to rise, CYP24A1 works in conjunction with CYP27B1 
to balance and refine tissue exposure to the active vitamin D hormone.  Target cell 
modification is crucial, as CYP24A1 fulfills the role of degrading 1,25(OH)2D after 
appropriate alterations in gene expression have occurred (71, 104). 
Vitamin D and Overweight/Obesity 
 It has been consistently reported in the literature that obese individuals are 
shown to have lower 25(OH)D levels compared to non-obese individuals, and further 
investigation into possible mechanisms is warranted as it has not been completely 
described to this point.  With the percentage of overweight/obese individuals in the US 
approaching 70% of the population and no slowdown in sight, important questions need 
to be addressed.  Is there an altered vitamin D metabolism in overweight/obese 
populations?  What effect does vitamin D supplementation have on this portion of 
society vs. healthy weight individuals?  Do overweight/obese individuals need a higher 
vitamin D supplementation level to correct a deficiency?    Is the response to vitamin D 
supplementation dependent on body size?  How does vitamin D status affect obesity?  
What are the effects of weight loss on 25(OH)D levels and vitamin D status?  What 
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direction must future research take to uncover the role of vitamin D supplementation in 
obesity prevention (118)? 
It has been reported by numerous researchers that overweight/obese individuals 
tend to have a worse vitamin D status than those with less adipose tissue (19, 70, 74, 90, 
100, 132).  Wortsman et al. (132) found that obese (BMI>30) subjects had lower basal 
25(OH)D concentrations than age-matched control subjects (BMI<25) (20.0 ± 3.4 ng/ml 
vs 33.9 ± 4.1 ng/ml); (p=0.017).  In the same study, after an identical exposure to UVB 
irradiation, the obese subjects had an increase in blood vitamin D3 concentration that 
was 57% less than the non-obese subjects (p=0.0042).  This significant difference in the 
response of the two groups (24 hrs after exposure) is possibly due to an increased 
sequestration of the synthesized vitamin D3 in the subcutaneous fat.  Thus, the obese 
subjects had similar precursor (7-DHC) levels and conversion to previtamin D3 and 
vitamin D3 in the skin, but the excess adipose tissue may have reduced the release of 
vitamin D3 into the circulation.  Adipose tissue, which stores vitamin D3, is much more 
available in the obese subjects to sequester this cutaneously synthesized vitamin D3.   
 Brock et al. (19) investigated a number of predictors of vitamin D status in a 
total of 2621 subjects (1357 males, 1264 females aged 55-74) from the Prostate, Lung, 
Colorectal, and Ovarian Cancer Screening Trial (PLCO).  They found a significant 
association (p<0.001) between  high BMI (≥30) and low vitamin D levels, again 
explaining this inverse relationship of 25(OH)D and obesity with the ―trapping‖ of 
vitamin D3 in the extra adipose tissue.  Interestingly, the odds ratio was much higher for 
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females vs. males (3.6 vs. 2.0) when looking at how a BMI >30 predicted vitamin D 
status.   
 Konradsen et al. (74) conducted a study of 2187 subjects (410 males, 1777 
females, aged 46.8±14.9) recruited from a metabolic and medical lifestyle management 
clinic in Norway.  They observed that as BMI increased there was a significant 
reduction (p<0.001) in serum 25(OH)D concentration.  Those that had a BMI >39.9 had 
serum 25(OH)D levels that were 24% lower than those with a healthy (<25) BMI. 
 Blum et al.(15) measured adipose tissue and serum vitamin D3 concentrations in 
17 obese subjects and found a moderately strong positive correlation between these 
measurements (0.68, p=0.003).  This is consistent with adipose tissue being a storage 
reservoir for vitamin D3 (not allowing it to arrive at the liver), thus also seeing low 
serum 25(OH)D status which is commonly seen in obese subjects.   
 Fat sequestration of vitamin D3 is not the only hypothesis for lower vitamin D 
status among overweight/obese individuals, and Drincic et al. (32) seem to have a much 
simpler explanation.  Utilizing a volumetric dilution model, they concluded that when 
serum 25(OH)D levels in the overweight/obese individuals are adjusted for body 
weight/size, there is no longer any difference between overweight/obese and healthy 
weight individuals in vitamin D status.  These authors actually concluded that for 
vitamin D deficient obese individuals, treatment should be based on body weight and a 
range of 70-80 IU/kg/day would be needed to produce individuals with sufficient 
vitamin D status.  The likely higher vitamin D requirement in the obese population and 
the idea that vitamin D intakes should be based on body weight/size has been illustrated 
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in numerous studies (4, 40, 41, 75, 77).  Thus, just knowing someone’s baseline vitamin 
D deficiency status alone is not enough, and BMI should be considered when 
recommending the dose and/or duration of vitamin D supplementation. 
 There is also evidence that for overweight/obese individuals, losing weight leads 
to improved vitamin D status, which could benefit overall health.  In a 2 year clinical 
weight loss trial of overweight/obese women, Rock et al. (99) found that those women 
who lost ≥ 10% of their baseline body weight increased their 25(OH)D levels by 5 
ng/ml vs 1.9 ng/ml for those women who did not lose any weight (P=0.014).  Vitamin D 
deficiency of all participants decreased from 49% to 36%, and only 17% of those that 
achieved a healthy BMI by the end of the study were considered vitamin D deficient. 
 It is not fully understood how vitamin D operates in human adipose tissue.  
Nimitphong et al. showed that VDR and CYP27B1 were expressed in human adipose 
tissue, preadipocytes, and newly differentiated adipocytes.  They hypothesize that active 
vitamin D hormone is involved in the healthy turnover and remodeling of adipose 
tissue, aiding in the creation of newly differentiated and more insulin-sensitive 
adipocytes, thus possibly helping with obesity and Type 2 Diabetes.  Further studies are 
needed to uncover the molecular mechanisms of active vitamin D hormone in adipose 
tissue (91, 109).   
 Adipose tissue expressing vitamin D metabolizing enzymes (25-hydroxylase, 
1α-hydroxylase (CYP27B1), 24-hydroxylase (catabolic CYP24A1)) and VDR has been 
demonstrated by Wamberg et al. as they compared this expression between lean and 
obese individuals.  They found decreased expression levels of 25-hydroxylase and 
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CYP27B1 by 71% (P˂0.0001) and 49% (P˂0.05), respectively, in the subcutaneous 
adipose tissue of the obese subjects.   The prevalence of low 25(OH)D levels 
(˂30ng/ml) was very high in the obese subjects compared to the lean subjects (90% vs 
50%).  Whether 25(OH)D created in adipose tissue contributes to circulating 25(OH)D 
levels is not currently known, and it is plausible that there could be increased 
catabolism (via CYP24A1) of vitamin D in obesity.  Wamberg et al. also analyzed 
CYP24A1 in obese subjects before and after a 10% weight loss and found that 
CYP24A1 expression increased by 79% (P˂0.05) after weight loss, signifying a 
possible  increased creation and use of 1,25(OH)2D within adipose tissue, followed by 
its degradation after positive effects (121). 
 These positive effects of 1,25(OH)2D within adipose tissue are important, as 
adipose tissue is not just a fatty acid storage reservoir but rather a highly metabolic 
tissue intimately involved in lipid and glucose metabolism.  A variety of hormones and 
cytokines are produced in adipose tissue, and a chronic inflammatory state along with 
adipose tissue dysfunction is associated with obesity.  An increased secretion of pro-
inflammatory cytokines (tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6)) 
by adipose tissue in obesity can lead to increased inflammation, macrophage 
infiltration, and increased endothelial adhesion leading to the promotion of 
atherosclerosis.  Vitamin D has anti-inflammatory effects, as an in vitro study by Zhang 
et al revealed a 25(OH)D dose-dependent, downregulation of IL-6 and TNF-α 
production in human monocytes.  Another in vitro study by Zehnder et al. demonstrated 
that human endothelial cell synthesis of 1,25(OH)2D is stimulated in response to 
inflammatory cytokines, illustrating an autocrine response mechanism, possibly 
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modulating endothelial cell adhesion and decreasing atherosclerosis progression (133, 
134). 
At the present time it is not fully understood how vitamin D is sequestered 
and/or mobilized from lipid storage and at what level of adiposity this may occur (18).  
It seems clear that our current obesity epidemic is contributing to our suboptimal 
vitamin D levels, as vitamin D deficiency/insufficiency is very common in 
overweight/obese individuals.  With this elevated prevalence of deficient vitamin D 
status in overweight/obese individuals and its associated comorbidities, regular vitamin 
D screening in this population seems warranted along with treatment options that are 
inexpensive and easy to implement (sensible sun exposure and vitamin D 
supplementation). 
Vitamin D and Type II Diabetes 
 Type II diabetes mellitus (T2DM) has become a serious health care problem, as 
this disease is exploding in prevalence and contributing to an ever increasing financial 
crisis in our health care system.  T2DM is associated with multiple co-morbidities and 
increased mortality.  As someone ages, how well they control their blood glucose 
appears to influence their health greatly and helps determine their risk for numerous 
chronic diseases.  New innovative techniques to help manage and prevent T2DM are 
needed, and vitamin D’s role in this is being explored more recently to possibly reduce 
the burden that T2DM has on its sufferers and on health care costs.  T2DM features a 
number of characteristics, including insulin resistance, altered insulin secretion, and 
thus hyperglycemia.  There are vitamin D receptors (VDR) in the pancreatic β-islet 
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cells, and thus 1,25(OH)2D  helps enhance insulin production and secretion (62).  
Insulin secretion also requires calcium, so vitamin D may contribute to maintaining 
proper insulin secretion by helping regulate ―extracellular calcium concentrations and 
flux through cell membranes in the beta cell‖ (95).   
 Evidence is accumulating that vitamin D may influence numerous factors that 
contribute to T2DM.  The majority of these studies are epidemiological or cross-
sectional, with intervention studies rather scarce.  With prevention of T2DM being the 
ultimate goal, being able to identify easily modifiable risk factors is crucial, as current 
recommendations (weight loss, improved nutrition) are not being followed adequately 
and are difficult to maintain for most people, evidenced by the incidence of T2DM 
increasing rapidly. 
 Numerous epidemiological studies show an inverse relationship between 
25(OH)D levels and a number of glycemic status measures, including fasting plasma 
glucose, OGTT, and insulin resistance (HOMA-R) (25, 42, 90, 96).  Fasting blood 
glucose is among the number of tests available to measure glycemic status, and is often 
among the first tests done to check for prediabetes and diabetes.  Need et al. (90) 
studied a large (n=753) group of postmenopausal white women, and on simple 
correlation found that fasting serum glucose was a negative function of serum 25(OH)D 
(p<0.001).  When the subjects were grouped according to their 25(OH)D levels, 
specifically comparing those with 25(OH)D levels up to 16 ng/ml (deficient vitamin D 
status) with those above 20 ng/ml, a significantly higher glucose level was found in the 
vitamin D deficient group (p<0.001).  The subjects were also divided into groups that 
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are up to 32 ng/ml (insufficient/deficient) and above 32 ng/ml (sufficient), and a 
significantly higher fasting serum glucose level was seen in the deficient/insufficient 
group (p=0.026). 
 Beydoun et al (14) examined a nationally representative sample of US adults 
(NHANES 2001-04), stratified by central obesity, and examined associations of 
25(OH)D with a number of metabolic disturbances (including fasting blood glucose).  
They found a stronger inverse association of 25(OH)D with fasting blood glucose 
among the subjects with central obesity (CO+) vs. subjects without central obesity (CO-
) (p<0.001).  With ~2/3 of the US population considered overweight or obese, this is a 
major concern for vitamin D status in the US.  In this study, hypovitaminosis D 
(25(OH)D < 20 ng/ml) was higher among subjects with CO+ vs. CO- group (37.7% vs. 
25.8%, p<0.0001).  With the associations seen in this study, in order to alleviate certain 
metabolic disturbances and reduce central obesity, behavioral changes that include 
improving their vitamin D status would be advisable. 
 Reiterating the importance of accurate identification of the VDR to try and 
understand the biological functions of vitamin D, it has been confirmed via the most 
recent, specific, and sensitive technique that VDR is indeed strongly expressed in 
pancreatic beta cells (124, 126).  The exact function is yet to be determined, but 
improved insulin secretion from beta cells as well decreased insulin resistance at target 
tissues are hypothesized.  The identification of a VDRE in the human insulin receptor 
promoter contributed to its proposed role in insulin sensitivity (81).  Human vitamin D 
supplementation studies for Type II Diabetes to date have had some sort of 
29 
 
 
shortcoming, whether it be too few subjects or too short an intervention.  Fortunately 
there are numerous large scale, randomized controlled trials looking at the role of 
vitamin D in Type II Diabetes ongoing, so some clarification will hopefully soon arrive 
when these studies are completed to what exactly is the role of vitamin D in Type II 
Diabetes prevention and treatment (131). 
Vitamin D and Cardiovascular Disease 
 Numerous cross-sectional studies have shown an association of hypovitaminosis 
D with a higher prevalence of cardiovascular disease (CVD) and its other risk factors 
(12, 23, 31, 34, 45, 73, 93, 106, 122, 136).  With CVD still the number one cause of 
death in the US and the prevalence of low vitamin D status, especially among middle-
aged and older adults, estimated to be approaching the percentages seen with those who 
are overweight/obese, there is a definite need to further our understanding of how 
vitamin D affects cardiovascular health. 
 There is substantial evidence to suggest that low levels of vitamin D may 
adversely affect cardiovascular health.  Not only is vitamin D associated with many risk 
factors for CVD, but it may be more directly related, with VDR located on vascular and 
cardiac cells (61, 122), although these results are now in question due to a more 
sensitive and specific VDR antibody that did not detect VDR in smooth muscle, heart 
muscle, or skeletal muscle (125, 126)  In addition to the obesity and fasting blood 
glucose already covered, vitamin D status also affects CV health via its association with 
hypertension. 
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 Evidence exists of 1,25(OH)2D regulating the major blood-pressure regulating 
hormone renin in the kidneys.  The active vitamin D hormone functions as an inhibitor 
of the renin-angiotensin system (RAS), which is beneficial as over-activation of RAS 
can lead to hypertension (78, 108).  Burgaz et al (21) determined from a meta-analysis 
of mostly cross-sectional studies that blood 25(OH)D concentration is inversely 
associated with hypertension.  They found that the OR for hypertension decreased by 
16% for every 16 ng/ml increase in blood 25(OH)D concentration.  Burgaz et al. looked 
at a community of elderly men, investigating the prevalence of hypertension in relation 
to 25(OH)D concentration.  They found that men with 25(OH)D concentration of <15 
ng/ml had a 3-fold higher prevalence of hypertension compared to men with a 
concentration ≥15 ng/ml.  They also hypothesized that the mechanism is the negative 
regulation of renin gene transcription via a vitamin D receptor-mediated mechanism 
(21, 79), and/or VDR and 1α-hydroxylase activity on blood vessel walls (112).  To this 
point there has not been consistency in reducing blood pressure with vitamin D 
supplementation in randomized controlled trials, so it is premature to recommend 
vitamin D supplementation for the prevention and treatment of hypertension. 
 Endothelial stress has been shown to induce the release of a novel growth factor, 
namely vitamin D binding protein (DBP).  If this stress on endothelial cells is 
consistently excessive, a dangerous situation can arise where normal responses to stress 
or injury can now become flawed repair processes that lead to high blood pressure, 
atherosclerosis, and increased risk of cardiovascular events.  With a low vitamin D 
status, DBP is released leading to the migration of vascular smooth muscle cells 
(VSMCs) to sites of endothelial dysfunction as part of the paracrine response for 
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vascular remodeling.  Phosphate and TNF-α (both increased in low vitamin D status) 
increase osteogenic processes in VSMCs which may increase the risk for vascular 
calcification, leading to increased blood pressure and increased risk of cardiovascular 
events.  Vitamin D plays a regulatory role during the endothelial response to injury, as 
25(OH)D and 1,25(OH)2D inhibit the growth and migration of VSMCs.  Thus when the 
vitamin D sterols are occupying the binding site (during sufficient vitamin D status) the 
signals to the VSMCs to proliferate and migrate are not activated, and vitamin D can 
potentially play a protective role to maintain vascular health (22, 98, 114). 
 Triglyceride levels are another CV risk factor that has been shown to be 
associated with low vitamin D status.  Martins et al. (82) looked at the prevalence of CV 
risk factors and 25(OH)D levels in the third NHANES.  After adjusting for age, gender, 
and race, 32.9% of people in the lowest quartile of vitamin D levels (<21 ng/ml) has TG 
levels of ≥150 mg/dl vs. 23.8% of those in the highest quartile (≥37 ng/ml).  This 
equated to an OR of 1.47 for high TG levels in individuals with low 25(OH)D levels. 
 High-density lipoprotein levels are now recognized as a risk factor for CV 
disease, as a level of ≥40 mg/dl or a total/HDL cholesterol ratio <5.0 is recommended to 
reduce CV disease risk.  In the NHANES 2001-2004 data, those that had a total/HDL 
cholesterol ratio <3.5 (38.7%) had a mean 25(OH)D level of 25.5 ng/ml vs. ≥5.0 
(23.9%) had a mean 25(OH)D level of 23.0 ng/ml (p<0.001) (44). 
 There is also an HDL hypothesis that postulates an elevated HDL level increases 
vitamin D levels, especially when vitamin D levels are typically suppressed (winter).  
Cholesterol is an important component of the barrier function of the skin, and during 
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times of stress (winter), more cholesterol is needed.  Cholesterol is available either by 
endogenous synthesis (via 7-DHC) or from the plasma (HDL scavenging for 
cholesterol).  If there is a reduction in cholesterol concentration for barrier function of 
the skin, then there is an increase in 7-DHC reductase activity (the enzyme that converts 
7-DHC to cholesterol).  But if you have an influx of cholesterol from your optimal HDL 
levels and its scavenging activity, then you will have an increased 7-DHC concentration 
for increased vitamin D synthesis (94). 
 Overall, components of metabolic syndrome, with its associated risk factors, 
increase the risk of CVD and diabetes.  Vitamin D appears to have an association with 
all the factors that make up metabolic syndrome, thus it could be advisable to identify 
vitamin D status as part of the screening process for these risk factors of chronic 
disease. 
Vitamin D and Cognitive Function  
 Vitamin D’s role in cognitive function is very intriguing to many researchers.  
With the high prevalence of vitamin D deficiency/insufficiency and Alzheimer’s and 
dementia becoming an ever increasing burden in an aging society, this potential link 
warrants further investigation.  A major hypothesis for the cause of Alzheimer’s and 
dementia is the vascular hypothesis, with cognitive dysfunction occurring secondarily to 
cerebrovascular or cardiovascular disease.  These blood vessels are at increased risk of 
damage with conditions such as endothelial dysfunction, HTN or T2DM present, and 
vitamin D’s role in ameliorating these diseases has been previously discussed.  Roman 
et al clarified a difference between vascular dementia and AD, as executive functions 
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(planning, problem solving, sequencing) are more profoundly affected than memory 
impairment (101).   
 The presence of VDR protein and 1α-hydroxylase and their distribution in the 
brain has been detected (33), but the antibodies used in previous studies were not VDR-
specific, so future studies will be required to confirm results (126).  They were 
previously co-localized in neurons and glial cells throughout parts of the brain most 
affected by cognitive disorders.  This leads to a compelling argument for a functional 
role for vitamin D in the human brain (20). 
 With aging, due to decreasing thickness of the skin and the reduction in the 7-
DHC content, the ability of the skin to synthesize vitamin D significantly decreases.  
MacLaughlin and Holick saw a ˃50% decrease in previtamin D3 production when 
comparing individuals in their 70’s vs teens.  While aging does not seem to negatively 
affect intestinal absorption of vitamin D, an increased incidence of non-alcoholic fatty 
liver disease (NAFLD) and age related functional decline of the kidneys can potentially 
has an adverse effect on the hydroxylation reactions that must occur to create the 
circulating and active forms of vitamin D (39, 80).   Combine this with low vitamin D 
dietary intake and limited sun exposure and it becomes clear why vitamin D deficiency 
is common in the elderly.  Older adults with Alzheimer’s disease (AD) have a very high 
prevalence, ~70-90%, of vitamin D deficiency (11, 61).   
 With evidence of the importance of sufficient vitamin D status for proper blood 
pressure control and endothelial function, Gorelick et al. (48) highlighted the 
importance of blood pressure control in middle-aged individuals for the prevention of 
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dementia later on in life.  The evidence is much more established for lowering blood 
pressure in mid-life rather than waiting until you are over the age of 80 for the 
prevention of dementia.  Being proactive about one’s vascular health and lowering 
blood pressure in patients with no cognitive impairment will reduce the risk of future 
cognitive problems. 
 There are a number of potential neuroprotective roles of vitamin D in regards to 
AD.  Active vitamin D (1,25(OH)2D) exerts its neurosteroid type actions through 
VDRs, which are present in neuronal and glial cells all throughout essential cognitive 
regions of the brain, including the hippocampus, hypothalamus, and cortex.  When 
1,25(OH)2D binds to VDR, this triggers neuronal protection via anti-inflammatory 
action, as AD is also an inflammatory brain disease with microglia located near the β-
amyloid (Aβ) plaques and increased release of TNF-α seen in several studies (16, 49).  
As previously discussed, vitamin D downregulates TNF-α production and promotes 
cytokines and macrophages to increase Aβ clearance.  In addition, 1,25(OH)2D-VDR 
complex stimulates neurotrophic agents, reduces Aβ42 peptide accumulation via Aβ 
peptide phagocytosis, and increases brain-to-blood Aβ efflux at the blood brain barrier.  
Finally, vitamin D regulates expression of various neurotransmitters in the brain, 
including acetylcholine, dopamine, and serotonin.  All of these neurosteroid 
characteristics of vitamin D may help to address cognitive decline in older adults (9, 43, 
103). 
 Scott et al. (105) analyzed data from the Nutrition and Memory in Elderly study 
(NAME).  After subjects completed a full neurological and psychiatric examination 
35 
 
 
along with an MRI, they found lower vitamin D concentrations (29.5 ng/ml vs. 16.5 
ng/ml; p=0.03) in patients with dementia than those without.  Also, using the cutoff of 
20 ng/ml, those below were associated with a higher prevalence of a possible or 
probable AD diagnosis (17.1% vs. 6.9%; p<0.01). 
 A main component of Alzheimer’s disease is defective clearance of Aβ protein.  
Masoumi et al.(83) combined 1,25(OH)2D with curcuminoids and stimulated 
macrophages to observe its actions on Aβ.  The result was that 1,25(OH)2D stimulated 
Aβ phagocytosis and clearance.  Maintaining sufficient vitamin D status may decrease 
neuronal cell death and decrease the risk for Alzheimer’s disease.  
 With an aging population and the growing health care costs as well as the 
financial and emotional burden of caring for the elderly, investigating easily 
implementable strategies to modulate risk factors and the pathology of cognitive 
dysfunction make sense.  Vitamin D fits this criteria, and maintaining an adequate 
vitamin D status may prove to be a cost-effective intervention in helping to delay 
cognitive dysfunction. 
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CHAPTER III 
METHODS 
Purpose 
The purpose of the present study was to investigate the relationship between 
current vitamin D status and risk factors (components of metabolic syndrome and 
cognitive dysfunction) for numerous chronic diseases (cardiovascular disease, diabetes, 
dementia) in men and women aged 50-70 years.  This study aimed to determine if 
deficient and/or insufficient vitamin D status was associated with risk factors 
(components of metabolic syndrome and cognitive dysfunction) for chronic disease 
(cardiovascular disease, diabetes, cognitive dysfunction). 
Subjects 
 Eighty-eight (88) recreationally active older individuals aged 50-70 years old 
were enrolled in this study.  One subject was realized to be age 72 after consenting, 
after which she was withdrawn from the study without any data collected.  Fifteen 
subjects completed the initial visit but did not return for the testing visit, as they did not 
respond to follow-up contact from the investigator.  Seventy-two (72) Caucasian 
recreationally active older individuals (54 females, 18 males) aged 50-70 years old 
completed this study.  Each subject completed the written informed consent along with 
a food frequency questionnaire and sun exposure questionnaire prior to participation in 
the study.  Participants volunteered from the Norman, OK (USA) area and surrounding 
communities. 
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Recruitment  
Subjects were recruited through word of mouth, emails, and flyers. Flyers were 
posted on the campus, as well as the prominent public places in and around Norman- 
Oklahoma City metropolitan area. 
Each volunteer read and signed a written informed consent form approved by 
the Institutional Review Board (IRB) at the University of Oklahoma, Norman.  
Inclusion Criteria 
1. Men and women aged 50-70 years old.  
2. Subjects weighed no more than 300 lbs. which was the weight limit of the DXA 
machine. 
3. Subjects had no cognitive problems that can interfere with their participation.  
Subjects                   must score greater than or equal to 27 points (out of 30) on 
the Mini Mental State Examination (MMSE) to indicate a normal cognition. 
4. Subjects were able to speak and understand English.  
Exclusion Criteria 
1. Individuals < 50 years old or > 70 years old. 
2.  Subjects weighing more than 300 lbs. 
3. Subjects with cognitive impairment that did not allow them to complete the 
current process or testing.  Subjects scoring less than 27 points (out of 30) on 
the MMSE. 
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Research Design 
 This study used a cross-sectional research design. All subjects completed an 
IPAQ questionnaire to estimate their sedentary/ active status. They also filled out a 
medical history, food frequency, and sun exposure questionnaire.  No intervention took 
place and data was collected during the spring/fall semester of 2013.  Eighty-eight (88) 
males and females aged 50-70 were recruited from the city of Norman, OK and 
surrounding communities and were consented and screened (questionnaires) for 
participation.  One subject was realized to be age 72 after consenting, after which she 
was withdrawn from the study without any data collected.  Fifteen subjects completed 
the initial visit but did not return for the testing visit, as they did not respond to follow-
up contact from the investigator.  Seventy-two (72) recreationally active older 
individuals (54 females, 18 males) aged 50-70 years old completed this study. 
Bone Mineral Density Measurements 
Dual Energy X-ray Absorptiometry (DXA, GE Lunar Prodigy, Prodigy encore 
software version 10.50.086, Madison, WI) assessed Total Body BMD (g/cm
2
) and a 
total body scan was performed in order to obtain % body fat and android/gynoid ratio 
(A/G Ratio).  The DXA machine was calibrated on each testing day prior to scanning 
subjects, and the scanning procedures were standardized for all participants.  Subjects 
dressed in light clothing with no attenuating materials (e.g., metal).  Subjects were 
placed in a supine position on the DXA table, arms were placed close to the sides of the 
body, and Velcro straps were placed around the knees and ankles to hold the legs 
together during the scans.  If the head of the subject did not appear within 2-3 sweeps of 
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the scan images, the scan was aborted for a new measurement after the subject had been 
repositioned.  A single technician performed all scans and analysis.  The lab %CV for 
the total body BMD was 0.6% and for % body fat was 1.87%.  
Body Composition 
Body composition was calculated from the total body scan to obtain % body fat 
and A/G Ratio.  Compared % body fat to norms of 15% for males and 25% for females.  
A/G Ratio > 1 for males and > 0.8 for females = increased chronic disease risk. 
Body Measurements 
Height was measured to the nearest 0.5 cm using a wall mounted stadiometer 
(Stadi-O-Meter, Novel Products Inc., Rockton, IL) without shoes.  The participant 
placed their heels together against the wall and was asked to stand up tall with back flat 
against the wall and their head aligned in the sagittal plane. Weight was measured to the 
nearest 0.1 kg using a digital bodyweight scale (TANITA BWB-800, TANITA, Japan) 
with the participant shoeless and wearing light weight clothing.  Body mass index 
(BMI) was calculated as body mass in kilograms divided by height in meters squared 
(kg/m2).  Waist circumference was measured to the nearest cm using a tape measure, at 
the top of the hip bone, level with the navel.  
Physical Activity 
To predict the status of an individual, the International Physical Activity 
Questionnaire (IPAQ) was used. The IPAQ has three categorical scores (low, moderate, 
high) for differentiating individuals on the basis of their physical activity (PA).  It asks 
about the time you have spent being physically active in the last 7 days.  There are 5 
parts: 1) Job related PA; 2) Transportation PA; 3) Housework, maintenance, caring for 
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family; 4) Recreation, sport, leisure-time PA; 5) Time spent sitting.  High PA: 7 
days/wk walking or moderate intensity activity accumulating at least 3000 MET-
minutes/wk or 3 days of vigorous activity and accumulating at least 1500 MET-
minutes/wk.  Moderate PA: 3 days of vigorous activity of at least 20 min per day or 5 
days of walking or moderate intensity activity for at least 30 min per day or 5 or more 
days of any combination of walking, moderate-intensity, or vigorous-intensity activities 
achieving at least 600-MET-min/wk.  Low PA: Those individual that do not meet the 
criteria for moderate or high PA.  This is the lowest level of PA. 
Sun Exposure 
  A sun exposure questionnaire was given to help assess sunlight exposure and 
illuminate the role of cutaneous vitamin D synthesis in vitamin D status.  A sun 
exposure recall questionnaire previously used by Hanwell et al (52) utilized 3 
components: 1) Sun Exposure Score (sum of the daily products of Time Outdoors and 
Skin Exposure); 2) Time Outdoors: 0 = <5 min; 1 = 5-30 min; 3 = > 30 min; 3) Amount 
of Skin Exposed: 1 = hands and face; 2 = hands, face, arms; 3 = hand, face, legs; 4 = 
bathing suit.  Range of the Sun Exposure Score is 0-56. 
Blood Pressure (BP) 
Brachial systolic (SBP) and diastolic BP (DBP) were measured using an 
automatic blood pressure measuring device (Omron IntelliSense Automatic Blood 
Pressure Monitor with Easy Wrap Cuff, model HEM-773AC, Vernon Hills, IL).  Two 
measurements were taken one minute apart on the right arm and averaged.  If these 
measurements were not within 5 mmHg, a third measurement was taken and used for 
analysis. 
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Pulse Wave Analysis (PWA) 
Applanation tonometry (SphygmoCor, AtCor Medical, Sydney, Australia) and a 
high-fidelity strain-gauge transducer (Miller Instruments, Houston, TX, USA) was used 
to obtain pressure waveforms at the radial artery on the right arm. Aortic blood pressure 
waveforms were derived from radial waveforms using a generalized validated transfer 
function (SphygmoCor, AtCor Medical, Sydney, Australia) to obtain measures of aortic 
blood pressure, arterial stiffness, and wave reflection. Two measurements with an 
operator index > 80 were obtained and the measurement with a higher operator index 
was used for analysis. 
Nutrient Analysis 
FoodWorks (The Nutrition Company, Long Valley, NJ) nutrient analysis 
software was utilized to analyze a 3-day food record (2 weekdays, 1 weekend day) for 
CHO, PRO, FAT, Calcium, and Vitamin D intake.  In addition, a food frequency 
questionnaire (Ca/Vitamin D) to assess vitamin D supplementation intake was 
administered. 
Blood Sampling 
Fasting blood samples were taken by trained personnel by venipuncture.  A lipid 
panel (Cholesterol, Triglycerides, HDL, LDL (calculated) Cholesterol/HDL Ratio 
(calculated)), Blood Glucose, and Vitamin D were measured. 
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Vitamin D Assay 
Vitamin D status was determined by Immunochemiluminometric assay (ICMA).  
This assay is performed on the DiaSorin LIAISON instrument by LabCorp.  Vitamin D 
sufficiency was defined as greater than or equal to 30 ng/ml. 
Cognitive Function 
      In cooperation with the Cognitive Science Research Center and the Center for 
the Study of Human Operator Performance (C-SHOP), the Automated 
Neuropsychological Assessment Metrics (ANAM4) test system was utilized to measure 
cognitive function.  A specific battery of tests was given in a specific order and the 
results were correlated with vitamin D status.  The following ANAM4 test order (with 
rationale and description) (5) was implemented:  
1) Simple Reaction Time  
 Cognitive Domain – ―Results of this test are used as an index of attention 
(i.e., reaction time & vigilance) and visuo-motor response timing.‖ 
 Test Description – ―This test measures simple reaction time by presenting 
the user with a series of "*" symbols on the display. The user is instructed to 
respond as quickly as possible by pressing a button each time the stimulus 
appears.‖ 
2) Code Substitution – Learning  
 Cognitive Domain – ―Results of this test are used as an index of complex 
scanning, visual tracking, and attention.‖ 
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 Test Description – ―In this test the user must compare a displayed digit-
symbol pair with a set of defined digit-symbol pairs, or the key. The user 
presses designated buttons to indicate whether the pair in question represents 
a correct or incorrect mapping relative to the key. In the Learning phase 
(simultaneous presentation mode), the defined pairs are presented on the 
screen along with the digit-symbol pair in question.‖ 
3)  Procedural Reaction Time  
 Cognitive Domain – ―This test measures the reaction time and processing 
efficiency associated with following a simple set of mapping rules.‖ 
 Test Description – ―There are three possible blocks of trials for this test. In 
the Basic Block, the user is presented with a number constructed on the 
display using a large dot matrix (either a 2, 3, 4, or 5). The user is instructed 
to press one designated button for a "low" number (2 or 3) and another 
designated button for a "high" number (4 or 5). In the Coded Block, the user 
is presented with the same numbers and mapping rules, but the numbers are 
visually distorted by the presence of noise in the matrix and are more 
difficult to read. In the Time-Uncertainty Block, the user is presented with 
the same undistorted stimuli and mapping rules as in the Basic Block, but at 
longer, irregular interstimulus intervals.‖ 
4)  Mathematical Processing 
 Cognitive Domain – ―Results of this test are used as an index of basic 
computational skills, concentration, and working memory.‖ 
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 Test Description – ―During this task, an arithmetic problem involving three 
single-digit numbers and two operators is displayed (e.g., "5 - 2 + 3 ="). The 
user presses buttons to indicate whether the answer to the problem is less 
than five or greater than five.‖ 
5) Matching to Sample  
 Cognitive Domain – ―Results of this test are used as an index of spatial 
processing and visuo-spatial working memory.‖ 
 Test Description – ―During this test the user views a pattern produced by 
eight shaded cells in a 4x4 sample grid. The sample is then removed and two 
comparison patterns are displayed side by side. One grid is identical to the 
sample grid and the other grid differs by one shaded cell. The user is 
instructed to press a designated button to select the grid that matches the 
sample.‖ 
6) 2-Choice Reaction Time  
 Cognitive Domain – ―Results of this test are used as a measure of processing 
speed and alternating attention with a motor speed component.‖ 
 Test Description – ―This test measures choice reaction time by presenting 
the user with a "*" or "o" on the display. The user is instructed to respond as 
quickly as possible by pressing the designated button for each stimulus as 
soon as the stimulus appears. This test can be modified to present alternative 
symbols as stimuli.‖ 
7) Code Substitution – Delayed 
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 Cognitive Domain – ―This test provides a measure of learning and delayed 
visual recognition memory.‖ 
 Test Description  – ―In this test the user is presented with a digit-symbol pair 
and must decide from memory if this pairing is correct based on the key 
presented during the Code Substitution — Learning test taken earlier in the 
test battery. The user presses designated buttons to indicate whether the pair 
in question represents a correct or incorrect match based on the earlier 
presented key.‖ 
This ANAM test gave a broad spectrum of analysis of cognitive processing in a 
very user friendly, efficient (~25 min) manner.  These tests utilized common pointing 
devices (mouse) and required minimal learning to master. 
Data Analysis 
All data were reported as mean ± standard error (SE). Data analysis was 
conducted using SPSS 19.0 (SPSS Inc., Chicago, IL) software, including descriptive 
statistics and 2 way ANOVA (PA, Gender) to determine between group differences for 
all outcome measures based on physical activity and gender.  Pearson correlation 
coefficients were used to explore potential relationships between serum 25(OH)D levels 
and disease risk factors.  A Chi-Square analysis involving VITD Status and Gender was 
conducted to examine the association and the sampling distribution between these two 
variables.  A Chi-Square analysis involving VITD Status and Physical Activity Level 
was conducted to examine the association and the sampling distribution between these 
two variables.  A one-way ANOVA was conducted to evaluate potential differences 
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across the three levels of vitamin D status (Deficient, Insufficient, Sufficient) for each 
risk factor for chronic disease.  Next, data was split based on Gender and Physical 
Activity Level.  A one-way ANOVA was conducted to evaluate potential differences 
across the three levels of vitamin D status (Deficient, Insufficient, Sufficient) for each 
Throughput score on the cognitive tests.  A Chi-Square analysis involving VITD Status 
and ANAM score (Average=all 7 tests scored average; Below Average=at least 1 test 
scored below average) was conducted to examine the association and the sampling 
distribution between these two variables.  A Chi-Square analysis involving VITD Status 
and VITD Synthesis was conducted to examine the association and the sampling 
distribution between these two variables.  The level of significance for all analyses was 
set at =0.05.   
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CHAPTER IV 
RESULTS & DISCUSSION 
Purpose 
 The purpose of the present study was to investigate the relationship between 
current vitamin D status and risk factors (components of metabolic syndrome and 
cognitive dysfunction) for numerous chronic diseases (cardiovascular disease, diabetes, 
dementia) in men and women aged 50-70 years.  This study aimed to determine if 
deficient and/or insufficient vitamin D status was associated with risk factors 
(components of metabolic syndrome and cognitive dysfunction) for chronic disease 
(cardiovascular disease, diabetes, cognitive dysfunction).   
Results 
 For each set of outcome variables, the data was first analyzed for the entire 
group (n=72) and then a two-way ANOVA examined the main effects of gender and 
physical activity levels on the outcome variables.  After a brief discussion of the group 
findings and the influence of gender on the variables, a separate table and discussion 
follows that examines the influence of physical activity on the variables. 
Participant Characteristics 
 On average, participants as a group, were overweight/obese based on their BMI 
(27.2) and % BF (38.2%) measures.  These numbers put individuals at increased risk for 
chronic disease.  Healthy BMI is 18.5-24.9 kg/m
2
, and while it is a tool to diagnose 
obesity, keep in mind that BMI does not distinguish between lean and fat mass.  The 
men averaged 29.1% BF and women 41.1% BF in this study, which categorizes both as 
obese, and well above the normal % BF for this population, which has an upper limit of 
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25% BF for females and 15% BF for males (1).  It appeared as though % BF tended to 
decline with increased PA, and 86% self-reported that they engaged in at least moderate 
physical activity on a regular basis, so that is encouraging for those obese individuals 
knowing that with hard work they can expect some positive body composition changes.  
A two-way ANOVA (Gender x Physical Activity Level) detected a significant main 
effect for gender as men and women differed significantly (p˂0.05) in the following 
characteristics:  1) Age (p=0.017); 2) standing height (p=0.000); 3) weight (p=0.006); 4) 
% body fat (p=0.000); 5) android/gynoid (A/G) ratio (p=0.000) (Table 1).  Men on 
average were older (+3.5yrs), taller (+15.5cm), heavier (+12kg), and had a larger A/G 
Ratio (1.2 vs .95) compared to women, who themselves had a higher %BF (+12.1%) 
compared to men.  With increasing PA there was an improvement in most body 
composition measures, especially for the women.  No interaction (p<0.05) (Gender x 
PA) was detected for any of these body composition variables. 
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Table 1.  Participant Characteristics 
 
Group N 
Age 
Ht. (cm) 
Wt. 
(kg) 
BMI %BF 
A/G 
Ratio 
WCcm 
Total 72 60.1 
(0.6) 
166.4 
(1.1) 
75.4 
(1.9) 
27.2 (0.6) 38.2 (1.1) 1.02 (.02) 96.0 
(1.6) 
Men 18 62.7 
(1.0) 
178.0 
(1.7) 
84.4 
(3.1) 
26.6 (0.8) 29.1 (1.4) 1.20 (.03) 98.8 
(2.2) 
Low 
PA 
0 n/a n/a n/a n/a n/a n/a n/a 
Mod 
PA 
10 62.4 
(1.5) 
175.6 
(2.2) 
82.7 
(5.3) 
26.7 (1.4) 29.2 (2.0) 1.19 (.04) 98.4 
(3.6) 
High 
PA 
8 63.1 
(1.5) 
181.0 
(2.5) 
86.6 
(2.5) 
26.4 (0.6) 29.0 (1.9) 1.21 (.06) 99.2 
(2.1) 
Women 54 59.2 
(0.7)* 
162.5 
(0.9)* 
72.4 
(2.2)* 
27.4 (0.8) 41.2 (1.1)* 0.95 
(.02)* 
95.1 
(1.9) 
Low 
PA 
10 59.3 
(1.6) 
161.2 
(2.2) 
80.9 
(7.7) 
30.9 (2.7) 46.2 (2.2) 0.98 (.04) 103.4 
(5.8) 
Mod 
PA 
23 59.1 
(1.1) 
163.8 
(1.5) 
76.0 
(2.9) 
28.5 (1.1) 43.4 (1.6) 0.97 (.03) 98.1 
(2.6) 
High 
PA 
21 59.2 
(1.3) 
162.3 
(1.3) 
64.5 
(2.0) 
24.5 (0.8) 36.5 (1.1) 0.93 (.04) 87.8 
(2.4) 
Data presented at mean (SE); BMI, body mass index; %BF, percentage body fat; A/G 
Ratio, android/gynoid ratio; WCcm, waist circumference in centimeters.  *p<0.05 vs. 
Men. 
 
 A two-way ANOVA detected a significant main effect for physical activity as a 
significant difference (p<0.05) was found between the different physical activity levels 
for BMI (p=0.019), % BF (p=0.006), and WCcm (p=0.028).  Least Significant 
Difference (LSD) post-hoc analysis revealed a significant decrease for BMI between 
Low PA and High PA (p=0.006); a significant decrease for % BF between Low PA and 
High PA (p=0.000) and between Low PA and Moderate PA (p=0.000); a significant 
decrease for WCcm between low PA and high PA (p=0.039).  BMI, %BF, and WCcm 
all decreased significantly with increased physical activity.  BMI mean values went 
from an obese categorization to healthy when going from low PA to high PA, along 
with %BF and WCcm being significantly lower, 11.8% and 12.4 cm respectively (Table 
2). 
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Table 2.  Participant Characteristics at Different Physical Activity Levels 
Group N 
Age 
Ht. (cm) 
Wt. 
(kg) 
BMI %BF 
A/G 
Ratio 
WCcm 
Total 72 60.1 
(0.6) 
166.4 
(1.1) 
75.4 
(1.9) 
27.2 
(0.6) 
38.2 
(1.1) 
1.02 
(.02) 
96.0 
(1.6) 
 Low 
PA 
10 59.3 
(1.6) 
161.2 
(2.2) 
80.9 
(7.7) 
30.9 
(2.7) 
46.2 
(2.2) 
0.98 
(.04) 
103.4 
(5.8) 
Mod PA 33 60.1 
(0.9) 
167.1 
(1.6) 
78.0 
(2.6) 
28.0 
(0.9) 
39.1** 
(1.7) 
1.03 
(.03) 
98.2 
(2.1) 
High 
PA 
29 60.3 
(1.0) 
167.4 
(2.0) 
70.6 
(2.5) 
25.0* 
(0.6) 
34.4* 
(1.1) 
1.01 
(.04) 
91.0* 
(2.1) 
Data presented at mean (SE); BMI, body mass index; %BF, percentage body fat; A/G 
Ratio, android/gynoid ratio; WCcm, waist circumference in centimeters.  *p<0.05 vs. 
low PA.  **p<0.05 vs. low PA.   
A Chi-square analysis involving VITD_Status and Gender was conducted to 
examine the association and the sampling distribution between these two variables  
(Table 3).  The association between the two variables was significant (p=0.008) and the 
results revealed that while exactly 50% (36 out of 72) of the study population was 
vitamin D deficient and/or insufficient, a higher percentage of males (12 out of 18 = 
66.6%) were vitamin D deficient and/or insufficient than females (24 out of 54 = 
44.4%).  In addition, a Chi-square analysis involving VITD_Status and Physical 
Activity Level was conducted to examine the association and the sampling distribution 
between these two variables (Table 4).  The association between the two variables was 
significant (p=0.002) and the results revealed that 70% (7 out of 10) of the low PA 
group, 51.5% (17 out of 33) of the moderate PA group, and 41.4% (12 out of 29) of the 
high PA group were vitamin D deficient and/or insufficient.   
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Table 3.  Chi-Square Analysis 
VITD_Status * GENDER Crosstabulation (p=0.008) 
 GENDER Total 
MALE FEMALE 
VITD_Status Deficient Count 0 9 9 
% within 
VITD_Status 
0.0% 100% 100.0% 
% within 
GENDER 
0.0% 16.7% 12.5% 
% of Total 0.0% 12.5% 12.5% 
Insufficient Count 12 15 27 
% within 
VITD_Status 
44.4% 55.6% 100.0% 
% within 
GENDER 
66.7% 27.8% 37.5% 
% of Total 16.7% 20.8% 37.5% 
Sufficient Count 6 30 36 
% within 
VITD_Status 
16.7% 83.3% 100.0% 
% within 
GENDER 
33.3% 55.6% 50.0% 
% of Total 8.3% 41.7% 50.0% 
Total  Count 18 54 72 
  % within 
VITD_Status 
25.0% 75% 100.0% 
  % within 
GENDER 
100.0% 100.0% 100.0% 
  % of Total 25% 75% 100% 
 
 
 
 
 
 
 
 
52 
 
 
Table 4. Chi-Square Analysis 
VITD_Status * Physical Activity (PA) Crosstabulation (p=0.002) 
 PHYSICAL ACTIVITY Total 
LOW MODERATE HIGH 
VITD_Status Deficient Count 5 1 3 9 
% within 
VITD_Status 
55.6% 11.1% 33.3% 100.0
% 
% within PA 50.0% 3.0% 10.3% 12.5% 
% of Total 6.9% 1.4% 4.2% 12.5% 
Insufficient Count 2 16 9 27 
% within 
VITD_Status 
7.4% 59.3% 33.3% 100.0
% 
% within PA 20.0% 48.5% 31.0% 37.5% 
% of Total 2.8% 22.2% 12.5% 37.5% 
Sufficient Count 3 16 17 36 
% within 
VITD_Status 
8.3% 44.4% 47.2 100.0
% 
% within 
GENDER 
30.0% 48.5% 58.6% 50.0% 
% of Total 4.2% 22.2% 23.6 50.0% 
Total  Count 10 33 29 72 
  % within 
VITD_Status 
13.9% 45.8% 40.3 100.0
% 
  % within PA 100.0% 100.0% 100.0% 100.0
% 
  % of Total 13.9% 45.8% 40.3% 100% 
  
Lipid Panel, Glucose, & Vitamin D 
 On average, as a group, the participants had normal lipid values with the 
exception of high LDL cholesterol (109.6 ±3.7), which remained high through all PA 
levels.  They also had high HDL cholesterol (64.8 ± 2.0), which is considered a 
negative risk factor for CHD when HDL-C ˃ 59 mg/dl.  Exercise has been shown to 
raise HDL levels, and both males and females increased HDL levels with increased PA.   
TGs also decreased with increased PA, and high TG levels, which have been shown in 
the literature to be associated with low vitamin D status, are associated with the lowest 
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vitamin D levels in this study.  Both TGs and circulating vitamin D levels (25(OH)D) 
were lowest in the low PA group.  Vitamin D levels as a group were sufficient 
(>30ng/ml) (31.1ng/ml) and increased with PA, especially for women going from 
insufficient to sufficient status.  Glucose levels as a group were normal and decreased 
with increasing PA.  Two-way ANOVA detected no significant main effect (p<0.05) for 
gender and no significant interaction (p<0.05) (Gender x PA) for the lipid panel, GLU, 
or VIT D (Table 5).   
Table 5.  Participant Blood Values 
Group N T Chol TG HDL LDL GLU VIT D 
Total 72 196.9 
(4.2) 
116.4 
(11.5) 
64.8 (2.0) 109.6 
(3.7) 
95.5 (3.4) 31.1 (1.3) 
Men 18 196.7 
(9.0) 
105.8 
(8.9) 
62.1 (3.4) 113.4 
(7.4) 
97.6 (3.1) 28.3 (1.3) 
Low PA 0 n/a n/a n/a  n/a n/a n/a 
Mod PA 10 187.1 
(12.4) 
58.3 
(4.6) 
58.3 (4.6) 106.7 
(10.2) 
99.2 (5.3) 27.5 (3.3) 
High PA 8 208.6 
(12.5) 
66.8 
(5.0) 
66.8 (5.0) 121.9 
(10.9) 
95.5 (2.7) 29.3 (3.7) 
Women 54 196.9 
(4.8) 
120.0 
(15.0) 
65.7 (2.4) 108.3 
(4.3) 
94.8 (4.4) 32.0 (1.7) 
Low PA 10 193.1 
(9.3) 
176.7 
(75.4) 
61.6 (7.1) 101.1 
(7.9) 
117.8 
(21.8) 
23.0 (3.3) 
Mod PA 23 198.1 
(7.8) 
119.0 
(10.1) 
62.1 (3.3) 112.2 
(5.8) 
88.2 (1.3) 34.8 (2.2) 
High PA 21 197.5 
(7.9) 
94.1 
(9.2) 
71.6 (3.6) 107.1 
(8.3) 
91.2 (3.2) 33.3 (2.3) 
Data presented as mean (SE); T Chol (mg/dl), total cholesterol; TG (mg/dl), 
triglycerides; HDL (mg/dl), high density lipoprotein; LDL (mg/dl), low density 
lipoprotein; GLU (mg/dl), glucose; Vit D (ng/ml), vitamin D (25(OH)D). 
 
Two-way ANOVA detected a significant main effect for physical activity level 
as a significant difference (p<0.05) was found between the different physical activity 
levels for GLU (p=0.018) and VIT D (p=0.014).  LSD post-hoc analysis revealed a 
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significant decrease for GLU between low PA and moderate PA (p=0.020) and between 
low PA and high PA (p=0.022), with lower GLU levels with increased PA; a significant 
increase for VIT D between low PA and moderate PA (p=0.038) and between low PA 
and high PA (p=0.040), with higher VIT D levels with increased PA.  Being at least 
moderately physically active tended to significantly decrease fasting glucose levels and 
increase circulating vitamin D levels compared to the low PA group. 
Table 6.  Participant Blood Values at Different Physical Activity Levels 
Group N 
T 
Chol 
TG HDL LDL GLU 
VIT D 
Total 72 196.9 
(4.2) 
116.4 
(11.5) 
64.8 (2.0) 109.6 
(3.7) 
95.5 (3.4) 31.1 (1.3) 
 Low PA 10 193.1 
(9.3) 
176.7 
(75.4) 
61.6 (7.1) 101.1 
(7.9) 
117.8 (21.8) 23.0 (3.3) 
Mod PA 33 194.8 
(6.6) 
116.4 
(7.7) 
61.0 (2.6) 110.6 
(5.0) 
91.5 (2.0)* 31.2 (2.0)* 
High PA 29 200.6 
(6.6) 
95.7 
(7.8) 
70.3 (2.9) 111.2 
(6.7) 
92.4 (2.5)* 31.3 (2.2)* 
Data presented as mean (SE); T Chol, total cholesterol; TG, triglycerides; HDL, high 
density lipoprotein; LDL, low density lipoprotein; GLU, glucose; VIT D, vitamin D.  
*p<0.05 vs. low PA. 
 
Total Caloric and Macronutrient Intakes 
Three-day average total caloric intake and macronutrient percentages of total 
caloric intake for participants are presented in Table 7.  Men and women were similar in 
all characteristics, with increased kcal intake with increased PA, and % kcal from FAT 
(34.4%) near the upper edge of the recommended range (35%).  Two way ANOVA 
detected no significant main effect (p<0.05) for gender and no significant interaction 
(p<0.05) (Gender x PA) for kcal and macronutrient intake.  As a total group the subjects  
met the Acceptable Macronutrient Distribution Range (AMDR) for CHO: 45-65% of 
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total kcals (47.5%); PRO: 10-35% of total kcals (17.9%); and FAT: 20-35% of total 
kcals (34.4%).  Fiber (AMDR = 30g for males 50-70 yrs; 21g for females 50-70 yrs) 
intake for men was low compared to the AMDR across all PA levels, while fiber intake 
for women was low in just the low PA category. 
Table 7.  Three day average total caloric intake, percentages of total daily caloric intake, 
and dietary fiber intake 
 
Group N Kcals % Kcal Fat % Kcal PRO % Kcal CHO Fiber (g) 
Total 72 1833.3 (76.8) 34.4 (1.0) 17.9 (0.6) 47.5 (1.1) 21.7 (1.2) 
Men 18 2021.9 (151.3) 32.6 (1.8) 18.5 (1.3) 49.0 (1.7) 22.9 (2.5) 
Low PA 0 n/a n/a n/a n/a n/a 
Mod PA 10 1959.4 (244.5) 31.7 (1.8) 17.2 (1.7) 52.7 (1.8) 25.7 (3.5) 
High PA 8 2100.1 (165.4) 33.8 (3.4) 20.2 (1.7) 44.4 (2.4) 19.5 (3.4) 
Women 54 1770.4 (88.2) 35.0 (1.2) 17.7 (0.6) 47.0 (1.3) 21.3 (1.4) 
Low PA 10 1289.8 (98.4) 35.2 (2.4) 17.6 (1.5) 45.4 (2.6) 15.9 (2.9) 
Mod PA 23 1878.0 (134.0) 36.7 (2.2) 18.1 (0.9) 46.7 (2.3) 21.7 (1.7) 
High PA 21 1881.5 (150.1) 33.1 (1.6) 17.3 (1.1) 48.1 (1.9) 23.4 (2.7) 
 Data presented as mean (SE); Kcals, calories; % Kcals, % of daily calories from    
nutrient. 
 
Two-way ANOVA detected a significant main effect (p<0.05) for physical 
activity levels as a significant difference (p<0.05) was found between the different 
physical activity levels for Kcals (p=0.015).  LSD post-hoc analysis revealed a 
significant increase for Kcals between low PA and moderate PA (p=0.024) and between 
low PA and high PA (p=0.017), as kcals increased with an increase in physical activity, 
which is typical as you need more kcals to fuel an active lifestyle so that you are not 
burning muscle for energy (Table 8). 
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Table 8.  Three day average total caloric intake, percentages of total caloric intake, 
and dietary fiber intake at different physical activity levels 
Group N Kcals % Kcal Fat % Kcal PRO % Kcal CHO Fiber (g) 
Total 72 1833.3 (76.8) 34.4 (1.0) 17.9 (0.6) 47.5 (1.1) 21.7 (1.2) 
 Low PA 10 1289.8 (98.4)* 35.2 (2.4) 17.6 (1.5) 45.4 (2.6) 15.9 (2.9) 
Mod PA 33 1902.6 (117.2) 35.2 (1.6) 17.8 (0.8) 48.5 (1.8) 22.9 (1.6) 
High PA 29 1941.8 (117.8) 33.3 (1.4) 18.1 (1.0) 47.1 (1.6) 22.3 (2.2) 
 Data presented as mean (SE); Kcals, calories; % Kcals, % of daily calories from 
nutrient.*p<0.05 vs. moderate PA and high PA. 
 
Systemic Hemodynamics 
 Two-way ANOVA detected no significant main effect for gender for brachial 
BP and HR measures (peripheral systolic blood pressure (P_SP): p=0.160; peripheral 
diastolic blood pressure (P_DP): p=0.497; peripheral mean arterial pressure 
(P_MEANP): p=0.930; heart rate (HR): p=0.528).  No main interaction effect (Gender x 
PA) was detected for any of the brachial BP and HR measures (P_SP: p=0.639; P_DP: 
p=0.419; P_MEANP: p=0.628; HR: p=0.339 (Table 9).  In addition, there was no 
significant main effect for physical activity levels for any hemodynamic variables.  
(P_SP: p=0.977; P_DP: p=0.702; P_MEANP: p=0.940; HR: p=0.244) (Table 10).  
These brachial BP and HR values are similar to normal values (120/80) you want to see 
for men and women in this age group. 
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Table 9.  Systemic Hemodynamics 
Group N P_SP P_DP P_MeanP HR 
Total 72 123.0 (1.6) 78 (0.9) 94.5 (1.1) 65.6 (1.1) 
Men 18 126.6 (2.4) 78.4 (1.4) 94.1 (1.7) 63.4 (2.0) 
Low PA 0 n/a n/a n/a n/a 
Mod PA 10 126.1 (3.5) 77.6 (1.7) 93.8 (2.3) 62.9 (3.0) 
High PA 8 127.1 (3.5) 79.5 (2.4) 94.5 (2.7) 64.1 (2.6) 
Women 54 121.2 (1.9) 77.6 (1.1) 94.6 (1.4) 66.3 (1.4) 
Low PA 10 120.9 (3.8) 79.3 (1.8) 95.3 (2.4) 70.7 (2.5) 
Mod PA 23 122.5 (3.4) 77.9 (1.8) 95.3 (2.4) 67.2 (2.0) 
High PA 21 120.0 (2.7) 76.4 (1.6) 93.4 (2.0) 63.2 (2.4) 
Data presented as mean (SE); P_SP (mmHg), peripheral systolic blood  
pressure; P_DP (mmHg), peripheral diastolic blood pressure; P_MEANP 
(mmHg), peripheral mean arterial pressure; HR (bpm), heart rate. 
 
 
Table 10.  Systemic Hemodynamics at Different Physical Activity Levels 
Group N P_SP P_DP P_MeanP HR 
Total 72 123.0 (1.6) 78 (0.9) 94.5 (1.1) 65.6 (1.1) 
Low PA 10 120.9 (3.8) 79.3 (1.8) 95.3 (2.4) 70.7 (2.5) 
Mod PA 33 123.6 (2.6) 77.8 (1.4) 94.9 (1.8) 65.9 (1.7) 
High PA 29 122.0 (2.2) 77.2 (1.4) 93.7 (1.6) 63.5 (1.9) 
Data presented as mean (SE); P_SP (mmHg), peripheral systolic blood  
pressure; P_DP (mmHg), peripheral diastolic blood pressure; P_MEANP 
(mmHg), peripheral mean arterial pressure; HR (bpm), heart rate.  
 
 
Central Hemodynamics 
 Two-way ANOVA detected a significant main effect (p=0.05) for gender for 
heart rate corrected central augmented pressure (C_AP_HR75) (p=0.000) and 
augmentation index (C_AGPH_HR75) (p=0.000).  These measures of arterial stiffness 
were much higher in the women, which indicates increased arterial stiffness compared 
to the men.  No significant interaction (Gender x PA) was detected (C_AP_HR75: 
p=0.833; C_AGPH_HR75: p=0.737; central systolic pressure (C_SP): p=0.773; central 
diastolic pressure (C_DP): p=0.434) (Table 11).  No significant main effect was 
58 
 
 
detected for physical activity on measures of central hemodynamics (C_AP_HR75: 
p=0.713; C_AGPH_HR75: p=0.309; C_SP: p=0.925; C_DP: p=0.725) (Table 12). 
Table 11.  Central Hemodynamics 
Group N C_AP_HR75 C_AGPH_HR75 C_SP C_DP 
Total 72 8.3 (0.5) 24.6 (1.3) 114 (1.5) 78.8 (0.9) 
Men 18 4.1 (0.7) 12.3 (2.0) 114.1 (2.2) 79.3 (1.4) 
Low PA 0 n/a n/a n/a n/a 
Mod PA 10 4.2 (1.0) 12.8 (2.5) 113.9 (3.1) 78.5 (1.7) 
High PA 8 3.9 (1.2) 11.8 (3.3) 114.3 (3.1) 80.3 (2.4) 
Women 54 9.8 (0.5)* 28.7 (1.2)* 114.5 (1.9) 78.6 (1.1) 
Low PA 10 9.4 (1.1) 29.6 (2.4) 113.7 (3.7) 80.4 (1.8) 
Mod PA 23 9.8 (0.8) 28.3 (1.6) 115.6 (3.5) 79.0 (1.8) 
High PA 21 9.9 (0.9) 28.9 (2.2) 113.8 (2.7) 77.4 (1.7) 
Data presented as mean (SE); C_AP_HR75, heart rate corrected central  
augmented pressure; C_AGPH_HR75, augmentation index; C_SP, central 
systolic pressure; C_DP, central diastolic pressure; *p<0.05 vs. Men. 
 
Table 12.  Central Hemodynamics at Different Physical Activity Levels 
Group N C_AP_HR75 C_AGPH_HR75 C_SP C_DP 
Total 72 8.3 (0.5) 24.6 (1.3) 114 (1.5) 78.8 (0.9) 
 Low PA 10 9.4 (1.1) 29.6 (2.4) 113.7 (3.7) 80.4 (1.8) 
Mod PA 33 8.1 (0.8) 23.6 (1.8) 115.1 (2.6) 78.8 (1.4) 
High PA 29 8.2 (0.9) 24.1 (2.3) 113.9 (2.1) 78.2 (1.4) 
Data presented as mean (SE); C_AP_HR75, heart rate corrected central  
augmented pressure; C_AGPH_HR75, augmentation index; C_SP, central 
systolic pressure; C_DP, central diastolic pressure.  
Dietary and Supplemental Vitamin D Intake 
 Three-day average of dietary and supplemental vitamin D intakes for 
participants are presented in Table 13.  Two way ANOVA detected no significant main 
effect (p<0.05) for gender for VITD IU (p=0.171) or VITD Supp (p=0.254) (Table 13).  
No significant main effect (p<0.05) for physical activity were detected for VitD IU 
(p=0.105) or VITD Supp (p=0.695) (Table 14).  A Pearson correlation was conducted to 
ascertain if VITD IU (dietary vitamin D) was correlated with VIT D (circulating levels 
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of vitamin D).  The correlation was low and not significant (r = 0.171; p=0.152).   
Gender (Males: r = 0.219; p=0.382, Females: r = 0.205; p=0.137) and physical activity 
level (low PA: r = 0.303; p=0.394, moderate PA: r = 0.052; p=0.772, high PA: r = 
0.174; p=0.366) had minimal effect on these relationships.  
Vitamin D is scarce in the diet and it is hard to meet the RDA (600 IU for ages 
51-70) by diet alone, which is illustrated by the average intake of 89 IU in this study.  
Thus dietary vitamin D only explains about 3% of the variance seen in circulating 
(25(OH)D) vitamin D levels.  A Pearson correlation was conducted to ascertain if VITD 
Supp (vitamin D supplement intake (IU)) was correlated with VIT D (circulating levels 
of vitamin D).  The correlation was moderate (r = 0.544; p=0.000), explaining ~30% of 
the variance seen in the circulating vitamin D levels.  Regarding gender, males (r = 
0.745; p=0.000) had a strong correlation, explaining ~55% of the variance seen in the 
circulating vitamin D levels, while females (r = 0.522; p=0.000) had a moderate 
correlation, explaining ~27% of the variance seen in circulating vitamin D levels.   
Table 13.  Dietary & Supplemental Vitamin D 
Group N Vit D (IU) 
Vit D Supp 
(IU) 
Total 72 89.0 (15.6) 1077.8 (201.1) 
Men 18 126.2 (31.4) 677.8 (186.4) 
Low PA 0 n/a n/a 
Mod PA 10 105.9 (28.3) 500.0 (227.5) 
High PA 8 151.7 (62.6) 900.0 (306.5) 
Women 54 76.6 (17.9) 1211.1 (259.2) 
Low PA 10 26.3 (8.6) 1280.0 (975.8) 
Mod PA 23 65.0 (20.0) 1504.4 (404.5) 
High PA 21 113.2 (39.4) 857.1 (213.8) 
Data presented as mean (SE); Vit D IU, dietary  
vitamin D in international units; Vit D Supp,  
supplemental vitamin D in international units. 
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Table 14.  Dietary & Supplemental Vitamin D at 
Different Physical Activity Levels  
Group N Vit D (IU) 
Vit D Supp 
(IU) 
Total 72 89.0 (15.6) 1077.8 (201.1) 
 Low PA 10 26.3 (8.6) 1280.0 (975.8) 
Mod PA 33 77.4 (16.4) 1200.0 (299.1) 
High PA 29 123.8 (32.9) 869.0 (173.6) 
Data presented as mean (SE); Vit D IU, dietary  
vitamin D in international units; Vit D Supp,  
supplemental vitamin D in international units.  
 
 
Sun Exposure 
 Two-way ANOVA detected no significant main effect for gender for SunExSc 
(p=0.973), TimeSun (p=0.522), or SkinExSc (p=0.837) (Table 15).  A significant main 
effect (p<0.05) was detected for physical activity for SunExSc (p=0.022) and SkinExSc 
(p=0.035).  LSD post-hoc analysis revealed a significant increase for SunExSc between 
low PA and high PA (p=0.019) and for SkinExSc between low PA and moderate PA 
(p=0.036), with higher scores with increased PA (Table 16).  For many individuals, 
increasing physical activity means getting outside for exercise and games in order to 
increase your sun exposure.  A Pearson correlation was conducted with VIT D 
(circulating levels) and the components of the sun exposure questionnaire: 1) Time 
Outdoors; 2) Amount of Skin Exposed; 3) Sun Exposure Score (sum of the daily 
products of Time Outdoors and Skin Exposed).  The correlations were not significant 
for any of the measures: SunExSc: r = 0.171; p=0.152; TimeSun: r = 0.046; p=0.701; 
SkinExSc: r = 0.165; p=0.165.  These results could be due to the time of year, which 
affects the ability to make vitamin D cutaneously from UVB radiation.  Also, SPF use 
was not documented in this study, as this can drastically reduce (>90%) the ability to 
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cutaneously synthesize vitamin D.  Many older individuals put on SPF before they step 
outside and have not been told about the benefits of sensible sun exposure.   
Table 15.  Sun Exposure 
Group N SunExSc TimeSun SkinExSc 
Total 72 19.4 (1.4) 9.1 (0.4) 13.5 (0.6) 
Men 18 19.4 (2.3) 9.6 (0.7) 13.7 (1.3) 
Low PA 0 n/a n/a n/a 
Mod PA 10 15.9 (2.2) 8.2 (0.7) 12.7 (1.3) 
High PA 8 23.9 (4.1) 11.3 (1.0) 15.0 (2.4) 
Women 54 19.3 (1.7) 8.9 (0.6) 13.4 (0.7) 
Low PA 10 10.2 (1.7) 7.0 (1.2) 9.6 (0.8) 
Mod PA 23 21.7 (2.6) 9.1 (0.9) 15.0 (1.1) 
High PA 21 21.1 (2.8) 9.5 (0.9) 13.5 (1.2) 
Data presented as mean (SE); SunExSc, sun exposure score; TimeSun, 
Time in the sun; SkinExSc, skin exposure score. 
 
Table 16.  Sun Exposure at Different Physical Activity Levels 
Group N SunExSc TimeSun SkinExSc 
Total 72 19.4 (1.4) 9.1 (0.4) 13.5 (0.6) 
 Low PA 10 10.2 (1.7)* 7.0 (1.2) 9.6 (0.8)** 
Mod PA 33 20.0 (2.0) 8.9 (0.6) 14.3 (0.9) 
High PA 29 21.8 (2.3) 10.0 (0.7) 13.9 (1.0) 
Data presented as mean (SE); SunExSc, sun exposure score; TimeSun, 
Time in the sun; SkinExSc, skin exposure score.  *p<0.05 vs.  
high PA; **p<0.05 vs. moderate PA. 
  
 
Cognitive Function 
 Prior to statistical analysis, a detailed examination of the data was conducted 
and data were screened to ensure validity and to look for outliers.  For the 2-Choice 
Reaction Time (CH2) test, one subject had a single test rescored due to mouse button 
reversal.  For the Simple Reaction Time (SRT) test, one subjects’ score was deemed an 
extreme outlier for being >3SD from the mean, and this score was eliminated.  Pearson 
correlation coefficients were calculated between the vitamin D level in the blood and 
the Throughput Scores on the cognitive tests.  No significant correlations were found 
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for any of the cognitive tests: 1) SRT: r = 0.065; p=0.591, 2) CDS: r = -0.142; p=0.235, 
3) PRO: r = 0.030; p=0.804, 4) MTH: r = 0.016; p=0.893, 5) M2S: r = -0.097; p=0.417, 
6) CH2: r = -0.097; p=0.600, 7) CDD: r = 0.054; p=0.651 (Table 17).   
A one-way ANOVA was conducted to evaluate potential differences across the 
three levels of vitamin D status (Deficient, Insufficient, Sufficient) for each Throughput 
score (Simple Reaction Time (SRT); Code Substitution Learning (CDS); Procedural 
Reaction Time (PRO); Mathematical Processing (MTH); Match to Sample (M2S); 2-
Choice Reaction Time (CH2); Code Substitution Delayed (CDD)).  No significant 
differences existed for each outcome variable across levels of vitamin D status.  1) SRT: 
p=0.394; 2) CDS: p= 0.860; 3) PRO: p=0.993; 4) MTH: p=0.837; 5) M2S: p=0.203; 6) 
CH2: p=0.796; 7) CDD: p=0.271 (Table 17).    
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Table 17.  Throughput scores 
 Total 
(25(OH)D) 
Group 1 
(Def) 
Group 2 
(Insuff) 
Group 
3 (Suff) 
p 
(ANOVA) 
r
a
 
N 72 9 27 36   
ANAM 
Tests, 
mean 
(std.) 
      
Simple 
Reaction 
Time 
217.6 
(262.8) 
207.4 
(33.7) 
215.9 
(27.6) 
221.1 
(24.5) 
.394 .07 
Code Sub 
Learning 
37.3 (7.6) 36.9 
(6.9) 
38.0 
(7.6) 
37.0 
(8.0) 
.860 -.14 
Proced 
React 
Time 
95.7 (13.4) 95.8 
(19.5) 
96.0 
(13.4) 
95.6 
(12.0) 
.993 .03 
Math 
Processing 
25.1 (6.6) 25.8 
(8.4) 
24.5 
(6.4) 
25.4 
(6.5) 
.837 .02 
Match to 
Sample 
28.3 (8.0) 27.2 
(8.4) 
30.4 
(7.3) 
26.9 
(8.3) 
.203 -.10 
2-Choice 
React 
Time 
126.1 
(15.3) 
125.6 
(15.1) 
124.7 
(16.2) 
127.4 
(15.1) 
.796 -.10 
Code Sub 
Delayed 
34.2 (11.2) 31.0 
(5.0) 
36.8 
(12.3) 
33.0 
(11.2) 
.271  .05 
a
Pearson correlation between vitamin D level and ANAM Throughput score.  
Throughput is a hybrid measure of reaction time and accuracy.  Reported as correct 
responses per minute.  Higher values indicate better performance.  P ANOVA, one-way  
ANOVA: Throughput scores across levels of vitamin D status (Deficient, Insufficient, 
Sufficient). 
The Automated Neuropsychological Assessment Metrics (ANAM) Performance 
Report was utilized to compare to age norms.  The ANAM Data Extraction & 
Prevention Tool (ADEPT) was utilized to classify subjects into one of three categories: 
1) Average or above; 2) Below average (<9
th
 %ile); 3) Clearly below average (<3
rd
 
%ile).  37.5% of subjects (27 out of 72) had at least 1 test below average or worse (<9
th
 
%ile), and 27.8% of subjects (20 out of 72) had at least 1 test clearly below average 
(<3
rd
 %ile).  A Chi-square analysis involving VITD Status and ANAM score 
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(Average=all 7 tests scored average; Below Average=at least 1 test scored below 
average) was conducted to examine the association and the sampling frequency between 
these two variables, and the association was not significant (p=0.766) (Table 18). 
 
Table 18.  Chi-Square Analysis 
ANAM  * VITD_Status Crosstabulation (p=0.766) 
Count 
 VITD_Status Total 
Deficient Insufficient Sufficient 
ANAM 
Tests 
Average 6 18 21 45 
Below 
Average 
3 9 15 27 
Total 9 27 36 72 
 
Vitamin D Levels (25(OH)D)/Vitamin D Status 
Pearson correlations were conducted to ascertain if circulating vitamin D levels 
(25(OH)D) was correlated with risk factors for chronic disease.  The correlations were 
significant but weak as 25(OH)D was negatively correlated with GLU (r = -0.377; 
p=0.001), TG (r = -0.266; p=0.024), and A/G Ratio (r = -0.317; p=0.007).  Thus, 
25(OH)D only accounts for ~14% of the variance in fasting glucose levels, ~7% of the 
variance in triglyceride levels, and ~10% of the variance seen in A/G Ratio.  Pearson 
correlations were also calculated to ascertain if 25(OH)D affects the risk for chronic 
disease differently for males and females.  For males, correlations were significant and 
moderate as 25(OH)D was negatively correlated with P_SP (r = -0.557; p=0.016), 
P_MEANP (r = -0.496; p=0.036), C_SP (r = -0.534; p=0.022).  Thus, 25(OH)D 
accounts for ~31% of the variance in P_SP, ~25% of the variance in P_MEANP, and 
~29% of the variance in C_SP.  For females, the correlations were significant but weak 
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as 25(OH)D was negatively correlated with GLU (r = -0.386; p=0.004), TG (r = -0.296; 
p=0.030), A/G Ratio (r = -0.425; p=0.001).  Thus, 25(OH)D accounts for ~15% of the 
variance in GLU, ~9% of the variance in TG, and ~18% of the variance in A/G Ratio.   
 One-way ANOVA was conducted to evaluate potential differences across the 
three levels of vitamin D status (Deficient, Insufficient, Sufficient) for each risk factor 
for chronic disease.  A significant main effect was detected for vitamin D status for 
GLU (p=0.001), TG (p=0.029), % BF (p=0.042), and A/G Ratio (p=0.007).  Least 
Significant Difference (LSD) post-hoc analysis revealed a significant decrease for GLU 
between Deficient Vitamin D Status and Insufficient Vitamin D Status (p=0.002) and 
between Deficient Vitamin D Status and Sufficient Vitamin D Status (p=0.000), with 
GLU levels decreasing as vitamin D status improved; a significant decrease for TG 
between Deficient Vitamin D Status and Insufficient Vitamin D Status (p=0.024) and 
between Deficient Vitamin D Status and Sufficient Vitamin D Status (p=0.009), with 
TG levels decreasing with improved vitamin D status; a significant decrease for % BF 
between Deficient Vitamin D Status and Insufficient Vitamin D Status (p=0.012) and 
between Deficient Vitamin D Status and Sufficient Vitamin D Status (p=0.047), with % 
BF decreasing with improved vitamin D status; a significant decrease in A/G Ratio 
between Insufficient Vitamin D Status and Sufficient Vitamin D Status, with A/G Ratio 
decreasing with improved vitamin D status.  Next, data was split based on gender and 
males had a significant difference for P_SP (p=0.016), P_MEANP (p=0.036), and C_SP 
(p=0.022), while females had a significant difference for GLU (p=0.003) and A/G Ratio 
(p=0.006).  LSD post-hoc analysis revealed a significant decrease for GLU in females 
between Deficient Vitamin D Status and Insufficient Vitamin D Status (p=0.004) and 
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between Deficient Vitamin D Status and Sufficient Vitamin D Status (p=0.001), with 
GLU decreasing in females with improved vitamin D status; a significant decrease in 
A/G Ratio in females between Deficient Vitamin D Status and Sufficient Vitamin D 
Status, with A/G Ratio decreasing in females with improved vitamin D status.  Post-hoc 
tests were not possible for males due to no males being in the Deficient Vitamin D 
Status group.  All differences in the males were between Insufficient and Sufficient 
Vitamin D Status.  Finally, data was split based on physical activity levels and the High 
Physical Activity Group had a significant difference for GLU (p=0.018) while Moderate 
Physical Activity Group had a significant difference for A/G Ratio (p=0.023).  The Low 
Physical Activity Group had no significant differences for any of the risk factors.  LSD 
post-hoc analysis revealed a significant decrease in GLU levels in the High Physical 
Activity Group between Deficient Vitamin D Status and Insufficient Vitamin D Status 
(p=0.044) and between Deficient Vitamin D Status and Sufficient Vitamin D Status 
(p=0.006).  Post-hoc tests were not possible for Moderate Physical Activity Group due 
to one Vitamin D Status Group (Deficient) having only 1 subject, thus all differences in 
Moderate Physical Activity Group were between Insufficient and Sufficient Vitamin D 
Status. 
 A Chi-square analysis involving VITD_Status and VITD Synthesis was 
conducted to examine the association between these two variables.  VITD Synthesis 
refers to the ability of an individual to synthesize vitamin D cutaneously via UVB 
radiation based on the time of year (1=March-October: Yes; 2=November-February: 
No).  This analysis evaluated the association and the sampling frequency between the 
date (VITD SYN1 = March-October; VITD SYN2 = November-February) the 
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participant had their vitamin D measured with their vitamin D status. The association 
between the two variables was significant (p=0.036) and the results revealed that 31.3% 
(5/16) of the subjects tested between November to February were vitamin D deficient 
vs. only 7% (4/56) of those tested during March to October were vitamin D deficient.  
Also, 53.6% (30/56) of those tested March to October were vitamin D sufficient vs. 
only 37.5% (6/16) of those tested November to February were vitamin D sufficient.  
Another finding indicated that 83.3% (30/36) of participants with sufficient (>30 ng/ml) 
vitamin D status were tested between March to October vs. only 16.7% (6/36) of those 
tested between November to February.  Finally, 62.5% of participants tested between 
November to February were not vitamin D sufficient (>30 ng/ml) (Table 19). 
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Table 19.  Chi-Square Analysis 
VITD_Status * VITD SYN Crosstabulation (p=0.036) 
 VITD SYN Total 
YES NO 
VITD_Status Deficient Count 4 5 9 
% within 
VITD_Status 
44.4% 55.6% 100.0% 
% within 
VITD SYN 
7.1% 31.3% 12.5% 
% of Total 5.6% 6.9% 12.5% 
Insufficient Count 22 5 27 
% within 
VITD_Status 
81.5% 18.5% 100.0% 
% within 
VITD SYN 
39.3% 31.3% 37.5% 
% of Total 30.6% 6.9% 37.5% 
Sufficient Count 30 6 36 
% within 
VITD_Status 
83.3% 16.7% 100.0% 
% within 
VITD SYN 
53.6% 37.5% 50.0% 
% of Total 41.7% 8.3% 50.0% 
Total  Count 56 16 72 
  % within 
VITD_Status 
77.8% 22.2% 100.0% 
  % within 
VITD SYN 
100.0% 100.0% 100.0% 
  % of Total 77.8% 22.2% 100% 
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Discussion 
 The primary objective of this study was to investigate any correlations between 
the current vitamin D status of the subjects and risk factors (components of metabolic 
syndrome and cognitive dysfunction) for chronic disease.  The population in this study 
(males and females aged 50-70) is ideal to investigate for numerous reasons.  Middle 
age to older adults in US society tend to accumulate body weight, add risk factors for 
chronic disease, and decrease physical activity.  Deficient/insufficient vitamin D status 
is common due in part to this decreased physical activity (less sun exposure), decreased 
capacity of cutaneous synthesis of vitamin D when actually exposed to UVB radiation, 
and few foods naturally containing vitamin D.  Many tissues and cells in the body have 
vitamin D receptors, thus research is ongoing and increasing to discover the link 
between vitamin D and many disease processes.   
Main Findings 
Circulating Vitamin D (25(OH)D) Levels/Vitamin D Status 
The main contributors to vitamin D status include sensible sun exposure, 
vitamin D supplementation, and dietary intake of vitamin D, usually in this descending 
order.  With older populations, sensible sun exposure is often minimal due to concerns 
over premature aging, decreased outdoor activities/exercise, and perceived skin cancer 
risk.  What contributed or was associated with vitamin D status for the subjects in this 
study is very interesting, and it requires an individual to be aware of his/her habits 
regarding vitamin D all year long.  The following will help describe what contributed to 
vitamin D status and vitamin D levels in this study.   
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In this study, exactly 50% (36 out of 72) of the study population was vitamin D 
deficient/insufficient (<30 ng/ml).  66.7% (12 out of 18) of the males were vitamin D 
deficient and/or insufficient vs. 44.4% (24 out of 54) of females, which is not 
unexpected due to a higher A/G Ratio and central obesity (70).  This is not unusual, as 
vitamin D deficiency/insufficiency is common in US adults due in part to less time 
spent outdoors, increased use of sunscreen and protective clothing while outdoors, and 
vitamin D not widely available in the food supply (36, 44).  These patterns were evident 
in this study population, as sensible sun exposure was minimal, explained by a mean 
sun exposure score of 19.4 (out of 56) which was equivalent to being outside most days 
of the week for only 10-15 minutes with minimal skin exposure (usually just hands and 
face, occasionally (1-2x/wk) exposing arms/legs).  Next, dietary intake of vitamin D 
was very low (mean of 89 IU), as the RDA for vitamin D for this age group is 600 IU/d.  
The average vitamin D supplement intake for these subjects was quite substantial at 
1078 IU, which moderately correlated with circulating vitamin D (25(OH)D levels (r = 
0.544; p=0.000).  This level of vitamin D supplementation is recommended by many 
vitamin D researchers in order to maintain a sufficient (>30ng/ml) vitamin D status (57, 
63).  The average circulating vitamin D (25(OH)D) level for all subjects was sufficient 
(>30ng/ml) at 31.1ng/ml.  In addition, 86% of the study subjects self-reported at least a 
moderate physical activity level, and there was a main effect for physical activity 
(p=0.014).  Average vitamin D levels were sufficient for the moderate and high physical 
activity groups and insufficient for the low physical activity group.  In fact, 70% of the 
subjects in the low physical activity group had Deficient and/or Insufficient Vitamin D 
Status vs. 51.5% and 41.4% in the moderate and high physical activity groups, 
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respectively.  Brock et al. (19) studied middle-aged men and women and also found that 
low vitamin D status is associated with physical inactivity, obesity, and low dietary 
vitamin D intake.  Vitamin D status was associated with GLU, TGs, % BF, and A/G 
Ratio in this study, with GLU, TGs, % BF, and A/G Ratio all decreasing with improved 
vitamin D status.  This is seen in the literature as low vitamin D status is associated with 
a wide variety of chronic disease risk factors (19, 25, 50, 69, 90, 100, 119). 
There is a strong association between the time of year that you get your vitamin 
D levels measured and your vitamin D status.  The crosstabulation analysis involving 
VITD_Status and VITD Synthesis really illustrates that it is more difficult to maintain 
sufficient vitamin D status during the winter months.  The findings of this analysis that 
were reported in the Results section are common themes seen across the country and in 
the research literature (127, 129).  It is very crucial that the public understand how 
diligent and consistent they must be with their dietary and supplemental vitamin D 
intake during the winter months in order to maintain sufficient (>30ng/ml) vitamin D 
status.  Norman, OK is at 35 degrees latitude, and research has shown that no vitamin D 
can be produced in the skin from sun exposure from November-to-February when living 
above 33 degrees latitude (129).  The solar zenith angle, which is the angle made by the 
sun’s light (vs vertical) is increased at higher latitudes and during the winter months, so 
that UVB radiation has to travel farther distances and gets absorbed by the ozone layer 
so less UVB photons reach the earth’s surface.  Combine this with up to a twofold 
decline in the epidermal stores of the vitamin D precursor 7-DHC with aging, and this 
older study population is at risk for vitamin D deficiency, especially in the winter 
months (80, 120).   
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 The importance of sensible sun exposure (without SPF, which reduces the 
capacity of the skin to make vitamin D by >95%) cannot be underestimated, as there are 
many advertisements, public service announcements, and even governmental programs 
that attempt to scare people away from the sun, and the general public is not exposed to 
the benefits of sensible sun exposure in the media.  Even Healthy People 2020 has a 
goal of a 10% improvement in the number of adults who report that they are very likely 
to limit their sun exposure, use sunscreen, or wear protective clothing.  In fact, the new 
RDAs for vitamin D were created for an individual receiving minimal sun exposure due 
to the perceived skin cancer risk and variability in cutaneous vitamin D synthesis via 
UVB radiation (102).  The message of the benefits of sensible sun exposure is clearly 
not getting out to the public at large, and this leads to a large portion of our population 
missing out on the best and easiest method of maintaining sufficient vitamin D status.   
 If an individual gets regular sensible sun exposure (preferably through exercise), 
eats breakfast everyday (vitamin D fortified breakfast foods like cereal, milk, orange 
juice, and eggs), and adds a vitamin D supplement (especially in the winter), they will 
take in the recommended 1000-2000 IU/d that most vitamin D researchers recommend 
to reach sufficient vitamin D status so that they can take advantage of the potential extra 
skeletal benefits. 
Body Composition and Vitamin D 
 Our results show that the females in the low PA group were the heaviest and had 
the highest BMI, %BF, A/G Ratio, WCcm, as well as the lowest circulating vitamin D 
(25(OH)D) levels.  These results put these females in the obese category and at 
increased risk for chronic disease.  The males in this study also had BMI, %BF, A/G 
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Ratio, and WCcm measures that put them in overweight/obese and at risk 
categorizations.  The least physically active males had the highest BMI, %BF, and 
WCcm and also had the lowest circulating vitamin D (25(OH)D) levels.  These results 
reinforce numerous studies where researchers found that overweight/obese individuals 
tend to have a worse vitamin D status than those with less adipose tissue (19, 68, 74, 90, 
100, 132).  The exact mechanism as to why overweight/obese individuals tend to have 
lower 25(OH)D levels is not completely understood.  Vitamin D sequestration inside 
adipose tissue is a possible explanation.  Worstman and Brock have both done studies 
where high BMI (>30) is significantly (p<0.05) associated with low 25(OH)D levels, 
with Worstman doing a UVB exposure study and the obese subjects had a 57% lower 
vitamin D3 concentration than the non-obese subjects after UVB exposure (19, 132).   
 There are other hypotheses for lower vitamin D status in overweight/obese 
individuals, and one of them also could lead to a strategy to improve vitamin D status.  
Drincic et al. (32) used a volumetric dilution model to conclude that if you adjust for 
body weight/size in these overweight/obese individuals, there is no longer any 
difference between overweight/obese and healthy individuals in vitamin D status.  They 
concluded that treatment based on body weight and a range of 70-80 IU/kg/day would 
be needed to produce sufficient vitamin D status in these overweight/obese individuals.  
Vitamin D intake based on body weight/size has been shown in numerous studies (4, 
40, 41, 75, 77), and having this knowledge creates an easy and effective strategy for the 
overweight/obese population to eliminate their vitamin D deficiency/insufficiency and 
help create a healthier environment in their metabolically active adipose tissue. 
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 In addition to knowing that one needs more vitamin D if they are 
overweight/obese, losing weight leads to improved 25(OH)D levels (99).  Losing 
weight via outdoor exercise is the optimal scenario in this situation, as vitamin D status 
would be improved not only by the weight loss but also by the sun exposure.  Adipose 
tissue expresses all of the vitamin D metabolizing enzymes (25-hydroxylase, 1α-
hydroxylase (CYP27B1), 24-hydroxylase (catabolic CYP24A1)) and VDR.  Decreased 
expression levels of these enzymes has been demonstrated in obese individuals.  But 
after weight loss an increased expression of CYP24A1 was seen, which possibly means 
the active form 1,25(OH)2D was created, exerted its positive effects, and then was 
degraded (121).  Subjects in this study, who were overweight/obese, were also fairly 
physically active, so if this activity level could result in weight loss, they could see an 
improvement in their 25(OH)D levels and an increase in the expression of their vitamin 
D metabolizing enzymes, which can lead to a healthier inflammatory environment, as 
vitamin D has anti-inflammatory effects.  This has potential implications for improving 
multiple components in cardiovascular disease prevention. 
Lipid Panel and Glucose 
 Adipose tissue is a highly metabolic tissue that is involved in lipid and glucose 
metabolism.  With the fact that subjects in this study were overweight/obese, this 
creates a chronic inflammatory state with adipose tissue dysfunction.  A variety of 
hormones and cytokines are produced in adipose tissue, and overweight/obese 
individuals have an increased secretion of pro-inflammatory cytokines (tumor necrosis 
factor-alpha (TNF-α) and interleukin-6 (IL-6) that can lead to increased inflammation, 
macrophage infiltration, and endothelial adhesion leading to increased risk of 
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atherosclerosis (50, 69, 119).  Vitamin D has anti-inflammatory effects, as a 25(OH)D 
dose dependent downregulation of TNF-α and IL-6 has been shown as well as 
endothelial cell synthesis of 1,25(OH)2D in response to inflammatory cytokines in vitro.  
Thus a sufficient vitamin D status would create an anti-inflammatory environment with 
the possibility of an autocrine response to combat atherosclerosis progression (133, 
134).  The subjects in this study had elevated LDL levels, as oxidized LDL initiates the 
cascade leading to inflammation, macrophage infiltration, and endothelial adhesion that 
leads to atherosclerosis.  Total cholesterol was borderline high for the subjects in this 
study, but this situation was helped out by the high HDL levels seen.  This elevated 
HDL level can potentially help the vitamin D status for these subjects, especially in the 
winter which we illustrated earlier is when subjects had the most difficulty maintaining 
sufficient vitamin D status.  Cholesterol plays an important role in the barrier function 
of the skin, especially during the winter when the outside elements create more stress 
and more cholesterol is needed.  Cholesterol is available either by endogenous synthesis 
(via 7-DHC) or from the plasma (HDL scavenging for cholesterol).  If there is a 
reduction in cholesterol concentration for barrier function in the skin, then 7-DHC 
reductase activity (the enzyme that converts 7-DHC to cholesterol) increases.  But with 
the optimal HDL concentration of the subjects, they will have an influx of cholesterol 
from its scavenging activity, thus allowing for increased 7-DHC concentration for 
increased vitamin D synthesis (94), provided you live below 33 degrees latitude.  
Exercise also increases HDL levels, which was illustrated both in the males and females 
in the study.  Triglycerides, another cardiovascular risk factor associated with low 
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vitamin D status (82), also decreased with increased physical activity in the females of 
the study.   
 As someone ages, how well their blood glucose is controlled seems to influence 
overall health greatly and helps determine chronic disease risk.  Overall, subjects who 
had normal fasting glucose levels, and lower glucose levels also had increased physical 
activity levels.  Subjects also had increasing vitamin D levels that parallel decreasing 
glucose levels.  This may be due to the fact that VDR are in pancreatic β-islet cells, and 
1,25(OH)2D3 helps enhance insulin production and secretion (62, 124, 126).  
Numerous studies have illustrated the inverse relationship between 25(OH)D levels and 
fasting glucose levels (25, 42, 90).  In addition to improved insulin secretion from β-
cells, decreased insulin resistance at target tissues is also hypothesized.  A vitamin D 
response element (VDRE) in the human insulin receptor promoter has been identified 
and is thought to contribute positively to insulin sensitivity (81).  Beydoun et al. (14) 
saw a stronger inverse association of 25(OH)D with fasting glucose among subjects 
with central adiposity vs. those without central adiposity.  Both men and women in this 
study had A/G Ratio and waist circumference values that put them at increased risk for 
chronic disease as well as lower 25(OH)D levels.  With increased central adiposity there 
is also an increased risk of developing non-alcoholic fatty liver disease (NAFLD).  
25(OH)D is produced in the liver, thus excess adipose tissue, especially central 
adiposity, can negatively affect circulating 25(OH)D levels.   
Dietary Intake 
 When taking into account the body composition, glucose, and lipid panel values 
of the subjects, it becomes apparent that improved dietary practices could improve these 
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outcome variables and decrease risk factors.  Percent of kcals from fat was at the upper 
end of the Acceptable Macronutrient Distribution Range (AMDR) for fat.  If subjects 
decreased their fat intake and increased their fiber intake, it would have a positive effect 
on their body fat levels and also their lipid levels, as dietary fiber decreases cholesterol 
levels in the body.  All subjects were low in their fiber intake and did not meet 
recommended levels (M: 38g/d; F: 25g/d). 
Hemodynamics 
 Blood pressure, peripheral and central, were at normal values for this study 
population.  With aortic pressure prominent in the heart, kidneys, and brain, many 
researchers believe that central pressure is related much stronger to cardiovascular 
events than brachial pressure (86).  With the overweight/obese situation of these study 
subjects, they are definitely at increased risk for hypertension.  This study did not 
control for blood pressure medication, and 25% of the subjects were taking some form 
of hypertensive medication.  Since the mean circulating vitamin D (25(OH)D levels for 
the study subjects was 31.1 ng/ml, those with sufficient vitamin D status could 
potentially garner benefits with better blood pressure control.  This is due to the fact that 
evidence exists that 1,25(OH)2D3 regulates the major blood pressure regulating 
hormone renin in the kidneys.  The active vitamin D hormone functions as an inhibitor 
of the renin-angiotensin system (RAS), which if over activated leads to hypertension.  
The hypothesized mechanism is a negative regulation of renin gene transcription via a 
VDR-mediated mechanism and/or VDR and 1α-hydroxylase activity on blood vessel 
walls (79, 108, 112).  Vitamin D binding protein (DBP), a novel growth factor, is 
released during endothelial stress.  If endothelial stress is consistently excessive, as in 
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hypertension, the repair process can become flawed and increase your risk for 
atherosclerosis and cardiovascular events.  DBP is released and leads to the migration of 
vascular smooth muscle cells (VSMCs) to sites of endothelial damage, which could 
occur in this study population due to their elevated LDL levels.  DBP only signals the 
VSMCs to proliferate and migrate if 25(OH)D and 1,25(OH)2D3   are not bound to its 
binding site.  Phosphate and TNF-α (both increased in low vitamin D status) increase 
osteogenic processes in VSMCs and may increase the risk for vascular calcification.  
Thus sufficient vitamin D status may play a protective role in maintaining vascular 
health (22, 98, 114).  The females in this study had elevated measures of arterial 
stiffness (C_AP_HR75, C_AGPH_HR75) compared to the males.  The females were 
the only gender that made up the low physical activity group, and the low physical 
activity group also had the lowest 25(OH)D levels.  The inability to properly protect 
and maintain vascular health due to low vitamin D levels is a potential explanation as to 
why females had higher arterial stiffness values. 
Cognitive Function 
 With vascular health being such a vital component of optimal cognitive 
functioning of the brain, it is easy to see how Alzheimer’s disease (AD) and dementia 
are major issues, with the cognitive dysfunction occurring secondarily to the 
cerebrovascular and cardiovascular disease seen in society today.  While 37.5% of 
subjects (27 out of 72) had at least 1 test below average or worse (<9
th
 %ile), and 27.8% 
of subjects (20 out of 72) had at least 1 test clearly below average (<3
rd
 %ile), a chi-
square analysis involving vitamin D status and ANAM scores (Average = all 7 tests 
scored average; Below Average = at least 1 test scored below average) was conducted 
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and the association between the two variables was not significant (p=0.766).  Our 
results regarding vitamin D and these tests of executive function (attention, processing 
speed, working memory, spatial processing) did not show an association, but Annweiler 
et al. (10) found that lower circulating vitamin D levels predicted executive dysfunction.  
Annweiler et al. (6) also concluded that <10 ng/ml seems to be the threshold that is 
most associated with cognition, as this would signify chronic hypovitaminosis D and 
has probably contributed to brain dysfunction over an extended period of time.   
When you combine the obesity, elevated LDL levels, and high dietary fat intake 
of these study subjects, they are at increased risk for cognitive dysfunction later in life.  
Gorelick et al. (48) highlighted the importance of controlling your blood pressure in 
mid-life to prevent dementia rather than wait until you are elderly.  Being proactive and 
trying to reduce or eliminate all risk factors for chronic disease will also help prevent 
cognitive dysfunction later in life.  Annweiler et al. (7) and other experts recently 
gathered  to discuss important points regarding vitamin D and cognition in older adults.  
They concluded that hypovitaminosis D (< 30 ng/ml) is a risk factor for cognitive 
disorders and that vitamin D supplementation should be implemented early in the care 
process to ensure vitamin D sufficiency (> 30ng/ml).  While vitamin D status by itself is 
not specific enough to diagnose cognitive disorders, it is part of the equation and with 
many biological targets throughout the body, vitamin D levels most likely contribute to 
the wide variety of symptoms seen in older adults with cognitive disorders.   
In addition to the anti-inflammatory and vascular maintenance properties of 
vitamin D that have already been mentioned, 1,25(OH)2D3  is being investigated for its 
role in stimulating amyloid-beta, the major protein that accumulates and effects neuron 
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function, phagocytosis and clearance (83).  Vitamin D is being combined with AD 
medication to see if it is more effective than the drug or vitamin D alone (8).  Vitamin D 
was combined with the AD drug Memantine and given to newly diagnosed AD patients 
for 6 months, and cognitive change was assessed with the Mini-Mental State 
Examination (MMSE), which is what was used in this study.  At 6 months, the 
memantine plus vitamin D group increased their MMSE score by 4.0 points and had a 
statistically and clinically relevant gain in cognition.  So vitamin D could possibly be 
part of the AD solution in a big way in the future.  With an aging population, vitamin D 
may play a role in maintaining cognitive function and be part of effective intervention 
to help delay cognitive dysfunction. 
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CHAPTER V 
CONCLUSIONS 
Purpose 
  The purpose of the present study was to investigate the relationship between 
current vitamin D status and risk factors (components of metabolic syndrome and 
cognitive dysfunction) for numerous chronic diseases (cardiovascular disease, diabetes, 
dementia) in men and women aged 50-70 years.  This study aimed to determine if 
deficient and/or insufficient vitamin D status was associated with risk factors 
(components of metabolic syndrome and cognitive dysfunction) for chronic disease 
(cardiovascular disease, diabetes, cognitive dysfunction).    
Hypotheses 
1. The vitamin D status of at least 50% of these older individuals will be 
deficient and/or insufficient. 
Yes, the results of the current study support this hypothesis.  Exactly 50% of the 
study population (36 out of 72) were vitamin D deficient (9) or insufficient (27). 
2. Deficient and/or insufficient vitamin D status will be associated with chronic 
disease risk factors. 
Yes, the results of the current study support this hypothesis.  Deficient and/or 
insufficient vitamin D status was associated with GLU, TGs, % BF, and A/G 
Ratio. 
3. Circulating vitamin D levels (25(OH)D) will correlate with risk factors for 
chronic disease and males will have stronger correlations with risk factors 
for chronic disease vs. females. 
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Yes, the results of the current study support this hypothesis.  For males the 
correlations were moderate as vitamin D levels were negatively correlated with 
P_SP (r = -0.557; p=0.016), P_MEANP (r = -0.496; p=0.036); C_SP (r = -0.534; 
p=0.022).  Thus, vitamin D levels account for ~31% of the variance in P_SP, 
~25% of the variance in P_MEANP, and ~29% of the variance in C_SP.  For 
females, the correlations were significant but weak as vitamin D levels were 
negatively correlated with GLU (r = -0.386; p=0.004), TG (r = -0.296; p=0.030), 
A/G Ratio (r = -0.425; p=0.001).  Thus, vitamin D levels account for ~15% of 
the variance in GLU, ~9% of the variance in TG, and ~18% of the variance in 
A/G Ratio. 
4. Dietary intake of vitamin D will not differ based on gender or physical 
activity level. 
Yes, the results of the current study support this hypothesis.  No significant main 
effect for gender for dietary vitamin D (p=0.171) or for physical activity for 
dietary vitamin D (p=0.105) was detected. 
5. Supplemental intake of vitamin D will not differ based on gender or physical 
activity level. 
Yes, the results of the current study support this hypothesis.  No significant main 
effect for gender for supplemental vitamin D (p=0.254) or for physical activity 
for supplemental vitamin D (p=0.695) was detected.   
6. Correlations between dietary intake of vitamin D and circulating levels of 
vitamin D (25(OH)D) will not differ based on gender or physical activity 
level. 
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Yes, the results of the current study support this hypothesis.  The correlation was 
low and not significant (r = 0.171; p=0.152) and gender and physical activity 
had minimal effect on these relationships. 
7. Circulating vitamin D levels (25(OH)D) will not correlate with Throughput 
scores on cognitive tests. 
Yes, the results of the current study support this hypothesis.  All the correlations 
were low and not significant. 
Subquestion Hypotheses 
1. A) The prevalence of deficient and/or insufficient vitamin D status will be 
greater in males vs. females. 
Yes, the results of the current study support this hypothesis.  66.7% (12 out of 
18) of the males were vitamin D deficient and/or insufficient vs. 44.4% (24 out 
of 54) of the females were vitamin D deficient and/or insufficient. 
      B) The prevalence of deficient and/or insufficient vitamin D status will be  
      greater in the low physical activity group vs. the moderate or high physical 
      activity group. 
Yes, the results of the current study support this hypothesis.  70% (7 out of 10) 
of the subjects in the low physical activity group were vitamin D deficient 
and/or insufficient vs. 51.5% (17 out of 33) and 41.4% (12 out of 29) for the 
moderate and high physical activity groups respectively. 
2. A) Males with a deficient and/or insufficient vitamin D status will be 
associated with more risk factors for chronic disease vs. females. 
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Yes, the results of the current study support this hypothesis.  Males with a 
deficient and/or insufficient vitamin D status were associated with 3 risk factors 
(P_SP, P_MEANP, C_SP) vs. 2 risk factors (GLU, A/G Ratio) for females. 
      B) Subjects in the low physical activity group with a deficient and/or  
      insufficient vitamin D status will not see a significant difference in risk 
      factors for chronic disease (across levels of vitamin D status) vs. subjects 
      in the moderate and high physical activity groups with a deficient and/or 
      insufficient vitamin D status. 
Yes, the results of the current study support this hypothesis.  No significant 
difference for any risk factor was seen in the low physical activity group 
between the different levels of Vitamin D Status, while a significant decrease in 
GLU levels was seen in the high physical activity group between Deficient 
Vitamin D Status and Sufficient Vitamin D Status (p=0.006).  In the moderate 
physical activity group a significant difference was seen for A/G Ratio between 
Insufficient Vitamin D Status and Sufficient Vitamin D Status (p=0.023). 
Strengths and Limitations 
 The results of this study are limited due to the cross-sectional design, thus you 
cannot draw cause-and-effect relationships with the participants’ vitamin D levels/status 
and their risk factors for chronic disease.  In addition, exclusion criteria did not include 
high blood pressure or cholesterol medication.  Recruitment was spread out over a 10 
month period, so when vitamin D status was assessed for 16 subjects, it was not 
possible to synthesize vitamin D cutaneously via UVB radiation because the sun angle 
was too low.  Next, the sun exposure questionnaire did not collect information 
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regarding sunscreen use or type of clothing worn.  In addition, there may not have been 
enough practice on the ANAM cognitive tests for sufficient familiarity and optimal 
performance, as the practice test was an abbreviated 5 minute version that was given 
only once, usually a week or more in advance of the actual test.  Finally, the low 
number of subjects (72) and gender discrepancy (54 females, 18 males) could affect 
variances and ANOVA results seen, and may result in a greater chance of a Type II 
error, or the failure to detect an effect that might be present. 
 This study’s strengths included a direct measure of circulating vitamin D levels, 
a 3-day food record, a vitamin D food/supplementation frequency questionnaire, and a 
sun exposure questionnaire in order to accurately assess vitamin D status and determine 
what components most contribute to one’s vitamin D status. 
Significance 
 This study confirmed that a deficient/insufficient vitamin D status is common in 
an older population and is associated with increased risk factors for chronic disease.  
Having physicians routinely assess vitamin D status in their patients, as part of an 
annual physical exam, just as they do for a lipid panel or fasting glucose, seems a 
logical next step.  In addition, there are several factors that are associated with an 
increased risk of developing vitamin D deficiency.  Physicians need to know that at risk 
populations include: 1) older adults, as the skin becomes less efficient at producing 
vitamin D with age due to diminished 7-DHC levels; 2) individuals with non-alcoholic 
fatty liver disease, which will continue to increase in the coming years due to the 
obesity epidemic.  25(OH)D synthesis occurs in the liver and this process can be 
compromised with a fatty liver; 3) individuals who live at higher latitudes or who spend 
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little time outside; 4) races with high melanin levels (African Americans, Native 
Americans, and Latinos) are at increased risk due to a reduced efficiency of vitamin D 
conversion in the skin.  Vitamin D deficiency/insufficiency will continue to be an issue 
in the future, especially with the obesity epidemic still on the rise.  Physicians need to 
begin to recommend sensible sun exposure to their patients, and incorporating that 
message when recommending increased physical activity would be valuable to the 
general public.  Once vitamin D deficiency/insufficiency is diagnosed, it can be 
remedied rather cheaply and effectively with sun exposure, supplementation, and 
dietary recommendations. 
Future Research 
 Future studies aimed at expanding on our findings need to include quality 
randomized controlled trials.  There is now plenty of epidemiological data out that 
supports potential links between low vitamin D levels and increased risk for chronic 
disease.  What is lacking are quality randomized controlled trials utilizing vitamin D 
supplementation.  25(OH)D can clearly be used as a biomarker for vitamin D status, but 
whether it can be a biomarker for certain health related outcomes has not been 
established and is still to be determined.  With the obesity epidemic there are ample 
opportunities for vitamin D supplementation in weight loss and exercise intervention 
studies.  Whether vitamin D can alter the incidence of chronic disease or its risk factors 
in vitamin D deficient/insufficient individuals has not been answered satisfactorily yet, 
and uncovering these mechanisms in the years and decades that follow will be 
intriguing. 
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E-mail Message 
 
 
 
I invite you to participate in a research study, titled ―Vitamin D Status: Associations 
With Chronic Disease Risk Factors and Cognitive Function.‖ 
The objective and purpose of this study is to investigate the relationship between 
current vitamin D status and risk factors (hypertension, metabolic syndrome, cognitive 
function) for numerous chronic diseases (cardiovascular disease, diabetes, dementia) in 
men and women aged 50-70 years. This study aims to determine if deficient and/or 
insufficient vitamin D status is associated with risk factors for chronic disease. 
The total commitment for this study is as follows: 1) An initial visit (about 60 minutes) 
to fill out consent forms and questionnaires; 2) One visit to OU Health Services 
(Goddard Health Center) for 1 blood draw (~15 minutes); 3) One testing session visit 
(~90 minutes) – height, weight, waist circumference, blood pressure, pulse wave 
analysis, DXA scan (body composition), and cognitive function computer generated 
assessment tests. 
This study requires that participants be fasting for the one blood draw. Participants will 
be exposed to a small amount of radiation due to the DXA scan 
Please let me know if you might be interested in this study and if there are any 
questions I might be able to answer for you. 
The University of Oklahoma is an Equal Opportunity Institution. Thank you for your 
interest. 
Steven L. Ferguson MS, RD, CSCS   
Steven.L.Ferguson-1@ou.edu 
The OU IRB has approved the content of this message but not the method of 
distribution. The OU IRB has no authority to approve distribution by mass email.  
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